[
    {
        "src_smiles": "c1ccc(-c2cc(NCc3cccnc3)n3nccc3n2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a phenyl ring connected to a complex heterocyclic system with multiple nitrogen atoms, including a pyrazole and a pyridine ring. The presence of nitrogen atoms suggests potential hydrogen bonding interactions, which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the nitrogen-rich heterocycles, which could aid in binding to the ATP-binding site of GSK3-beta. However, the overall size and flexibility might limit optimal binding.\",\n    \"Limitation in Source Molecule for Property\": \"The molecule may lack sufficient hydrophobicity for optimal binding to the hydrophobic regions of GSK3-beta. Additionally, the presence of multiple nitrogen atoms could lead to undesired metabolic instability or poor pharmacokinetic properties.\",\n    \"Optimization for Source Molecule\": \"To improve GSK3-beta inhibition, consider: 1) Introducing hydrophobic substituents (e.g., methyl, fluoro) on the phenyl ring to enhance binding to hydrophobic pockets. 2) Reducing the number of nitrogen atoms in the heterocyclic system to improve metabolic stability. 3) Adding a hydrogen bond donor/acceptor group to strengthen interactions with the kinase.\",\n    \"Final Target Molecule\": \"c1ccc(-c2cc(NCc3cccnc3)n3nccc3n2)cc1\"\n}\n```"
    },
    {
        "src_smiles": "O=c1cc(Br)c2cccc([N+](=O)[O-])c2[nH]1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule is a brominated and nitrated indole derivative. It contains a bromine atom at the 3-position of the indole ring and a nitro group at the 5-position. The indole core is a common scaffold in medicinal chemistry, known for its ability to interact with various biological targets, including kinases.\",\n    \"Property Analysis\": \"The nitro group and bromine atom may contribute to the molecule's ability to inhibit GSK3-beta, but the nitro group's electron-withdrawing nature could reduce the nucleophilicity of the indole nitrogen, potentially affecting binding affinity. The bromine atom's size and hydrophobicity might be beneficial for binding but could also introduce steric hindrance.\",\n    \"Limitation in Source Molecule for Property\": \"The nitro group's strong electron-withdrawing effect may reduce the basicity of the indole nitrogen, which is often important for hydrogen bonding with the kinase. Additionally, the bromine atom's size might cause steric clashes with the binding site, reducing potency. The molecule's overall polarity might also limit cell permeability.\",\n    \"Optimization for Source Molecule\": \"1. Replace the nitro group with a less electron-withdrawing substituent (e.g., methoxy or methyl) to increase the basicity of the indole nitrogen. 2. Replace the bromine atom with a smaller, more flexible group (e.g., chlorine or fluorine) to reduce steric hindrance. 3. Consider adding a small hydrophobic group (e.g., methyl) at the 2-position to enhance binding interactions. 4. Introduce a hydrogen bond donor/acceptor at the 6-position to improve interactions with the kinase.\",\n    \"Final Target Molecule\": \"O=c1cc(Cl)c2cccc(Oc3ccccc3)c2[nH]1\"\n}\n```"
    },
    {
        "src_smiles": "O=C(O)c1ccccc1Nc1ccnc(N2CCCCC2)n1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a benzoic acid derivative linked to an aminopyrimidine ring via an aniline bridge. The pyrimidine ring is further substituted with a piperidine group. Key features include the carboxylic acid group, aromatic rings, and the secondary amine linkage.\",\n    \"Property Analysis\": \"The molecule has potential for GSK3-beta inhibition due to the presence of hydrogen bond donors (carboxylic acid and secondary amine) and acceptors (pyrimidine nitrogen and carbonyl oxygen), which can interact with the ATP-binding site of GSK3-beta. However, the carboxylic acid may limit cell permeability.\",\n    \"Limitation in Source Molecule for Property\": \"The carboxylic acid group may reduce cell permeability and bioavailability. The aniline linkage might be metabolically unstable. The piperidine ring's conformation may not optimally fit the hydrophobic pocket of GSK3-beta.\",\n    \"Optimization for Source Molecule\": \"1. Replace the carboxylic acid with a bioisostere like a tetrazole or sulfonamide to improve permeability while retaining hydrogen bonding. 2. Modify the aniline linkage to a more stable alkylamine or incorporate it into a heterocycle. 3. Optimize the piperidine ring size or substitution to better fit the hydrophobic pocket. 4. Introduce additional hydrophobic groups to enhance binding affinity.\",\n    \"Final Target Molecule\": \"O=C(Nc1ccnc(N2CCCC2)n1)c1ccccc1N1CCCC1\"\n}\n```"
    },
    {
        "src_smiles": "COc1cc2ncnc(N(C)c3ccc(C)c(Cl)c3)c2cc1OC",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring (c2ncnc) fused to a benzene ring (c1cc2cc1), with two methoxy groups (OC) attached to the benzene ring. There is also a substituted aniline group (N(C)c3ccc(C)c(Cl)c3) attached to the pyrimidine nitrogen.\",\n    \"Property Analysis\": \"The molecule has potential for GSK3-beta inhibition due to the presence of the pyrimidine core, which can act as a hinge binder, and the substituted aniline group, which can provide additional interactions with the kinase. However, the methoxy groups may limit solubility and the chlorine substituent may affect binding affinity.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy groups may reduce solubility and membrane permeability. The chlorine substituent on the aniline ring may not optimally interact with the kinase's hydrophobic pocket, potentially limiting binding affinity.\",\n    \"Optimization for Source Molecule\": \"Replace the methoxy groups with more polar and soluble groups like hydroxyl or amine groups to improve solubility. Modify the chlorine substituent to a smaller or more hydrophobic group like fluorine or methyl to better fit the hydrophobic pocket of GSK3-beta. Consider adding a hydrogen bond donor or acceptor to the aniline ring to enhance interactions with the kinase.\",\n    \"Final Target Molecule\": \"COc1cc2ncnc(N(C)c3ccc(C)c(F)c3)c2cc1O\"\n}\n```"
    },
    {
        "src_smiles": "COc1ccc(-c2cc3c(NCc4ccccc4)ncnc3o2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a benzoxazole core linked to a methoxy-substituted phenyl ring via a single bond. The benzoxazole is further substituted with a piperazine ring, which is connected to a phenyl group. This structure suggests potential for hydrogen bonding and \u03c0-\u03c0 interactions, which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the presence of the methoxy group and the benzoxazole core. The piperazine ring may contribute to basicity and solubility, which could affect binding affinity to GSK3-beta. The phenyl rings may engage in hydrophobic interactions with the target.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy group may not provide optimal hydrogen bonding interactions with the target. The piperazine ring, while basic, may not be positioned to maximize interactions with key residues in the GSK3-beta binding site. The overall molecular weight and flexibility might also limit binding affinity.\",\n    \"Optimization for Source Molecule\": \"To improve GSK3-beta inhibition, consider replacing the methoxy group with a more polar substituent like a hydroxyl or amino group to enhance hydrogen bonding. The piperazine ring could be replaced with a more rigid or constrained amine to better fit the binding site. Introducing additional hydrophobic or aromatic groups could also improve binding affinity.\",\n    \"Final Target Molecule\": \"COc1ccc(-c2cc3c(NCc4ccccc4)ncnc3O)cc1\"\n}\n```"
    },
    {
        "src_smiles": "CNc1nn2c(C)cc(CO)nc2c1S(=O)(=O)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a sulfonyl group (S(=O)(=O)) attached to a phenyl ring, a methyl-substituted imidazo[1,2-b]pyridazine core with a hydroxymethyl group, and a dimethylamino substituent. The imidazo[1,2-b]pyridazine core is a known scaffold for kinase inhibition, and the sulfonyl group may contribute to binding via hydrogen bonding or electrostatic interactions.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the sulfonyl and hydroxymethyl groups, which could aid in solubility and binding to GSK3-beta. The dimethylamino group may provide basicity, potentially influencing the molecule's interaction with the kinase's ATP-binding site.\",\n    \"Limitation in Source Molecule for Property\": \"The hydroxymethyl group may not optimally interact with the hinge region of GSK3-beta. The dimethylamino group's basicity might be too high, leading to off-target effects or poor selectivity. The sulfonyl group's orientation may not maximize interactions with the kinase's binding pocket.\",\n    \"Optimization for Source Molecule\": \"1. Replace the hydroxymethyl group with a more rigid or hydrogen-bond-accepting group (e.g., carbonyl or heterocycle) to enhance hinge region binding. 2. Modify the dimethylamino group to a less basic or more sterically constrained amine (e.g., pyrrolidine) to improve selectivity. 3. Adjust the sulfonyl group's position or replace it with a bioisostere (e.g., sulfonamide or carboxylate) to optimize binding interactions.\",\n    \"Final Target Molecule\": \"CN1CCN(C)c2nn3c(C)cc(C(=O)Nc4ccccc4)nc3c2S(=O)(=O)c5ccccc5\"\n}\n```"
    },
    {
        "src_smiles": "Nc1nonc1-c1nc2ccccc2n1Cc1ccncc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a central imidazo[1,2-a]pyridine core (Nc1nonc1-c1nc2ccccc2n1) linked to a pyridine ring (Cc1ccncc1) via a methylene bridge. The imidazo[1,2-a]pyridine core is a known pharmacophore for kinase inhibition, while the pyridine ring may contribute to solubility and binding interactions.\",\n    \"Property Analysis\": \"The molecule has moderate potential for GSK3-beta inhibition due to the presence of the imidazo[1,2-a]pyridine core, which can interact with the ATP-binding site. However, the pyridine ring may not optimally contribute to binding affinity or selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"1. The pyridine ring may not provide sufficient hydrophobic interactions or hydrogen bonding for optimal GSK3-beta binding. 2. The methylene linker may limit conformational flexibility needed for optimal binding. 3. Lack of additional hydrogen bond donors/acceptors to enhance interactions with the kinase.\",\n    \"Optimization for Source Molecule\": \"1. Replace the pyridine ring with a more hydrophobic aromatic ring (e.g., phenyl with electron-withdrawing groups) to enhance binding affinity. 2. Introduce a hydrogen bond donor/acceptor (e.g., NH2 or OH) at the 5-position of the imidazo[1,2-a]pyridine core to improve interactions with the hinge region. 3. Consider extending the methylene linker to an ethylene or propylene linker for better flexibility and positioning.\",\n    \"Final Target Molecule\": \"Nc1nonc1-c1nc2ccccc2n1CCc1ccc(N)cc1\"\n}\n```"
    },
    {
        "src_smiles": "CC(C)=Cc1ccc2cc(NC(=O)C3CC3)ncc2c1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule features a central indole core (c1ccc2ccncc2c1) substituted with a tert-butyl group (CC(C)=C) at position 2 and an amide-linked cyclopropyl group (NC(=O)C3CC3) at position 5. The indole scaffold is a common pharmacophore in kinase inhibitors, and the cyclopropyl amide may engage in hydrogen bonding with the kinase hinge region.\",\n    \"Property Analysis\": \"The molecule's indole core and amide group suggest potential for GSK3-beta inhibition, but the bulky tert-butyl group may hinder optimal binding due to steric clashes in the ATP-binding site. The cyclopropyl amide, while a good hinge binder, might lack additional interactions for high potency.\",\n    \"Limitation in Source Molecule for Property\": \"1. Tert-butyl group may cause steric hindrance in the ATP-binding pocket. 2. Cyclopropyl amide, though a hinge binder, may not fully exploit additional subpockets (e.g., hydrophobic back pocket or ribose pocket). 3. Lack of polar interactions with key residues like Asp133 or Lys85.\",\n    \"Optimization for Source Molecule\": \"1. Replace tert-butyl with a smaller hydrophobic group (e.g., methyl or chloro) to reduce steric clash. 2. Extend the cyclopropyl amide into a bulkier, more flexible group (e.g., piperazine or morpholine) to engage the back pocket. 3. Introduce a hydrogen bond donor/acceptor (e.g., hydroxyl or pyridine) near position 7 to interact with Lys85 or Asp133. 4. Consider fluorination to improve metabolic stability.\",\n    \"Final Target Molecule\": \"CC1=Cc2ccc(NC(=O)C3CCNCC3)cc2N1\"\n}\n```"
    },
    {
        "src_smiles": "CCc1[nH]c2ccc(OC)cc2c1C1=CCNCC1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a benzimidazole core (with a methyl group at position 2), a methoxy-substituted phenyl ring, and a piperidine ring linked via a methylene bridge. The benzimidazole and phenyl rings provide aromaticity and potential for hydrogen bonding, while the piperidine offers basicity and conformational flexibility.\",\n    \"Property Analysis\": \"GSK3-beta inhibitors often feature hydrogen bond donors/acceptors, aromatic rings for stacking interactions, and basic nitrogen atoms for ionic interactions with the kinase's ATP-binding site. The current structure lacks strong hydrogen bond donors and may have suboptimal steric fit.\",\n    \"Limitation in Source Molecule for Property\": \"1) Weak hydrogen bonding capacity (only one NH in benzimidazole). 2) Methoxy group may not optimally interact with the hinge region. 3) Piperidine's basicity might lead to off-target effects. 4) Limited hydrophobic interactions with the kinase's back pocket.\",\n    \"Optimization for Source Molecule\": \"1) Replace methoxy with a hydrogen bond donor (e.g., hydroxyl). 2) Introduce a sulfonamide or amide group at the benzimidazole 5-position for additional hinge region interactions. 3) Replace piperidine with a more constrained, less basic group (e.g., morpholine). 4) Add a hydrophobic substituent (e.g., chloro) to enhance binding pocket interactions.\",\n    \"Final Target Molecule\": \"CC1=NC2=CC=C(O)C=C2N1C1=CNCCO1\"\n}\n```"
    },
    {
        "src_smiles": "Cc1ccc(-c2nnc(SCc3ccccc3)o2)c(O)c1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a central thiazole ring (c2nnc(SCc3ccccc3)o2) connected to a phenol group (c1ccc(O)c1) and a methyl group (Cc1). The thiazole ring is further substituted with a phenylthioether (SCc3ccccc3). The molecule has potential for hydrogen bonding via the phenol group and the nitrogen atoms in the thiazole ring.\",\n    \"Property Analysis\": \"GSK3-beta inhibition often requires molecules that can form hydrogen bonds with key residues in the ATP-binding pocket, such as Asp133 and Val135. The presence of the phenol group and the nitrogen atoms in the thiazole ring suggests some potential for interaction, but the overall structure may lack optimal binding affinity and selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"The phenylthioether group (SCc3ccccc3) may not contribute significantly to binding affinity and could introduce metabolic instability. The methyl group (Cc1) may not provide optimal steric or electronic effects for binding. The phenol group, while capable of hydrogen bonding, may not be optimally positioned for interactions with key residues.\",\n    \"Optimization for Source Molecule\": \"1. Replace the phenylthioether group with a more polar and hydrogen-bond-accepting group, such as a sulfonamide or a carboxamide, to enhance interactions with the ATP-binding pocket. 2. Introduce a more electron-withdrawing group than the methyl group to improve electronic effects and potential hydrogen bonding. 3. Consider adding a small, polar substituent to the phenol ring to enhance solubility and binding affinity. 4. Explore the introduction of a fused ring system to the thiazole to increase rigidity and potentially improve binding.\",\n    \"Final Target Molecule\": \"O=C(Nc1ccc(O)c(Cl)c1)c2nnc(SC(=O)Nc3ccccc3)o2\"\n}\n```"
    },
    {
        "src_smiles": "O=C(O)CSc1nonc1-c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a carboxylic acid group (-COOH) attached to a thioether (S-CH2) linked to a non-aromatic heterocycle (1,2,5-oxadiazole, 'non') fused to a benzene ring. The presence of the carboxylic acid may contribute to hydrogen bonding but could limit cell permeability.\",\n    \"Property Analysis\": \"The molecule lacks features typically associated with GSK3-beta inhibition, such as a planar aromatic system for pi-stacking or hydrogen bond acceptors/donors for active site interactions. The thioether and oxadiazole may offer some binding but are not optimized for GSK3-beta.\",\n    \"Limitation in Source Molecule for Property\": \"1) Carboxylic acid may reduce cell permeability. 2) Lack of strong hydrogen bond donors/acceptors for GSK3-beta active site. 3) The oxadiazole ring may not provide optimal geometry for binding.\",\n    \"Optimization for Source Molecule\": \"1) Replace -COOH with bioisostere (e.g., tetrazole or acyl sulfonamide) to improve permeability while retaining H-bonding. 2) Introduce a planar aromatic system (e.g., pyridine or pyrimidine) to enhance pi-stacking. 3) Add a hydrogen bond donor (e.g., NH2) near the oxadiazole for active site interaction. 4) Consider replacing thioether with a more rigid linker (e.g., amide).\",\n    \"Final Target Molecule\": \"O=C(Nc1nonc1-c1ccccc1)c1cnn1-c1ccccc1\"\n}\n```"
    },
    {
        "src_smiles": "CN(C)c1ccc(C(=O)NCc2ccccc2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a dimethylamino group attached to a phenyl ring, which is further connected to a benzamide moiety via a carbonyl group. The benzamide part is linked to a phenyl ring through a methylene bridge.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the presence of the dimethylamino and amide groups. The aromatic rings contribute to its hydrophobicity. The amide group may engage in hydrogen bonding, which is crucial for GSK3-beta inhibition.\",\n    \"Limitation in Source Molecule for Property\": \"The dimethylamino group may not provide optimal interaction with the GSK3-beta active site. The flexibility of the methylene bridge might reduce binding affinity. The lack of additional hydrogen bond donors/acceptors could limit interactions with the kinase.\",\n    \"Optimization for Source Molecule\": \"1. Replace the dimethylamino group with a more rigid and polar group like a piperazine or morpholine to enhance binding. 2. Introduce a hydrogen bond donor/acceptor on the benzamide phenyl ring to improve interactions. 3. Constrain the methylene bridge by incorporating it into a ring system to reduce flexibility.\",\n    \"Final Target Molecule\": \"O=C(NCc1ccccc1)c2ccc(N3CCOCC3)cc2\"\n}\n```"
    },
    {
        "src_smiles": "Nc1ccccc1NC(=O)c1ccc(CNc2ncccn2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains an aniline group (Nc1ccccc1) connected to a benzamide (NC(=O)c1ccc(CNc2ncccn2)cc1) with a pendant aminopyridine (CNc2ncccn2) group. The molecule has hydrogen bond donors (NH groups) and acceptors (carbonyl and pyridine nitrogen), which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule has moderate potential for GSK3-beta inhibition due to its hydrogen bonding capabilities and aromatic systems. However, the flexibility of the linker (CH2 group) and the basicity of the pyridine nitrogen might limit its binding affinity and selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"The flexible CH2 linker may reduce binding affinity due to entropy loss upon binding. The basic pyridine nitrogen could lead to off-target interactions or poor pharmacokinetic properties. The aniline group may also be metabolically unstable.\",\n    \"Optimization for Source Molecule\": \"1. Replace the flexible CH2 linker with a more rigid group (e.g., a phenyl ring or a double bond) to reduce entropy loss. 2. Replace the pyridine with a less basic heterocycle (e.g., pyrimidine) to improve selectivity. 3. Modify the aniline group to improve metabolic stability (e.g., replace with a pyridine or fluorinated benzene). 4. Introduce additional hydrogen bond acceptors/donors to enhance binding affinity.\",\n    \"Final Target Molecule\": \"Nc1ccc(NC(=O)c2ccc(C=Nc3ncncn3)cc2)cc1\"\n}\n```"
    },
    {
        "src_smiles": "COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a benzimidazole core with a methoxy group at position 1, an amino group at position 2, and a phenyl ring attached via a urea linkage. The benzimidazole core is a common pharmacophore in kinase inhibitors, and the urea moiety can participate in hydrogen bonding interactions with the target enzyme.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the presence of the urea and amino groups, which can facilitate binding to the polar active site of GSK3-beta. However, the methoxy group may not contribute significantly to binding affinity or selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy group at position 1 of the benzimidazole may not be optimal for GSK3-beta inhibition, as it does not participate in hydrogen bonding or other strong interactions with the enzyme. Additionally, the phenyl ring attached via the urea linkage may not be optimally positioned for interactions with hydrophobic pockets in the active site.\",\n    \"Optimization for Source Molecule\": \"To improve GSK3-beta inhibition, consider replacing the methoxy group with a more polar substituent that can form hydrogen bonds with the enzyme, such as a hydroxyl or amino group. Additionally, the phenyl ring could be replaced with a more hydrophobic or bulky group to better fit into the hydrophobic pockets of the active site. Introducing a halogen or a heterocycle on the phenyl ring could also enhance binding affinity.\",\n    \"Final Target Molecule\": \"Oc1n[nH]c2cc(NC(=O)NC(C)c3ccc(Cl)cc3)ncc12\"\n}\n```"
    },
    {
        "src_smiles": "CCC(C)Nc1ncnc2cc(OC)c(OC)cc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a purine core (ncnc1) with two methoxy groups (OC) on the phenyl ring and an isopropylamino (CCC(C)N) substituent. The structure suggests potential for GSK3-beta inhibition due to the purine scaffold, which is known to interact with the ATP-binding site of kinases.\",\n    \"Property Analysis\": \"The molecule has moderate lipophilicity due to the isopropyl group and methoxy substituents, which may affect its solubility and permeability. The purine core is a common pharmacophore in kinase inhibitors, but the current substituents may not optimize binding affinity or selectivity for GSK3-beta.\",\n    \"Limitation in Source Molecule for Property\": \"The isopropylamino group may not provide optimal interactions with the hinge region of GSK3-beta. The methoxy groups may contribute to steric hindrance or suboptimal electronic properties for binding. The molecule lacks hydrogen bond donors/acceptors that could enhance interactions with key residues in the GSK3-beta binding site.\",\n    \"Optimization for Source Molecule\": \"1. Replace the isopropylamino group with a more polar or hydrogen-bonding group (e.g., cyclopropylamino or hydroxyethylamino) to improve hinge region interactions. 2. Modify the methoxy groups to smaller or more electron-withdrawing substituents (e.g., fluoro or chloro) to reduce steric hindrance and improve electronic complementarity. 3. Introduce a hydrogen bond donor/acceptor (e.g., NH2 or OH) at the 6-position of the purine to enhance interactions with the kinase backbone.\",\n    \"Final Target Molecule\": \"CC1CC1Nc1ncnc2cc(F)c(F)cc12\"\n}\n```"
    },
    {
        "src_smiles": "COC(=O)CSc1nc(-c2ccc(F)cc2)c(-c2ccncc2)[nH]1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a thiazole core with a fluorine-substituted phenyl ring and a pyridine ring attached. The thiazole nitrogen is protonated (NH), and there is a methyl ester group (COOCH3) attached via a sulfur linker.\",\n    \"Property Analysis\": \"The molecule has moderate size (MW ~300) and lipophilicity (cLogP ~2.5). The fluorine atom may enhance binding through halogen bonding, while the pyridine nitrogen could act as a hydrogen bond acceptor. The ester group might be metabolically unstable.\",\n    \"Limitation in Source Molecule for Property\": \"1) The ester group may lead to rapid hydrolysis in vivo, reducing bioavailability. 2) The protonated NH in thiazole may limit membrane permeability. 3) The pyridine ring's basic nitrogen could lead to off-target interactions.\",\n    \"Optimization for Source Molecule\": \"1) Replace the ester with a more stable amide or heterocycle. 2) Consider N-methylation of the thiazole NH to improve permeability. 3) Explore bioisosteric replacements for the pyridine (e.g., pyrimidine). 4) Introduce additional hydrogen bond donors/acceptors in the phenyl ring region to enhance GSK3\u03b2 binding.\",\n    \"Final Target Molecule\": \"CN1C(=O)CSc2nc(-c3ccc(F)cc3)c(-c3cncn3)n2\"\n}\n```"
    },
    {
        "src_smiles": "Cc1cccc2[nH]c(-c3ccccn3)nc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule is a benzimidazole derivative with a phenyl and a pyridine substituent. The benzimidazole core is a known pharmacophore for kinase inhibition, including GSK3-beta. The molecule has a planar structure with potential for hydrogen bonding via the NH group in the benzimidazole ring and the nitrogen in the pyridine ring.\",\n    \"Property Analysis\": \"The molecule has moderate lipophilicity due to the aromatic rings and may have limited solubility. The presence of the pyridine ring could contribute to binding affinity via hydrogen bonding or pi-stacking interactions with the kinase. However, the lack of additional hydrogen bond donors/acceptors or hydrophobic substituents may limit its potency and selectivity for GSK3-beta.\",\n    \"Limitation in Source Molecule for Property\": \"1. Limited hydrogen bonding capacity: Only one NH group and one pyridine nitrogen are available for interactions with the kinase. 2. Lack of hydrophobic substituents: The molecule may not optimally fill hydrophobic pockets in the GSK3-beta binding site. 3. Potential metabolic instability due to the unsubstituted benzimidazole NH and the pyridine ring.\",\n    \"Optimization for Source Molecule\": \"1. Introduce a hydrogen bond donor/acceptor at the 5 or 6 position of the benzimidazole core to enhance interactions with the kinase hinge region. 2. Add a hydrophobic substituent (e.g., methyl, chloro, or fluoro) to the phenyl ring to improve binding affinity. 3. Replace the pyridine ring with a more electron-rich heterocycle (e.g., pyrrole or imidazole) to enhance pi-stacking interactions. 4. Consider substituting the benzimidazole NH with a small alkyl group to improve metabolic stability.\",\n    \"Final Target Molecule\": \"Cc1cccc2[nH]c(-c3ccccn3)c(C(=O)N)c12\"\n}\n```"
    },
    {
        "src_smiles": "CN1CCC(c2c[nH]c3ccc(N=C(N)c4cccs4)cc23)CC1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central piperidine ring (CN1CCC) connected to a fused bicyclic system (c2c[nH]c3ccc(N=C(N)c4cccs4)cc23). The bicyclic system includes an indole-like structure with an additional nitrogen in the five-membered ring and a thiophene ring (c4cccs4) attached via an imine (N=C) linkage. The molecule has multiple hydrogen bond acceptors (N, S) and donors (NH).\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to its ability to form hydrogen bonds and its planar, aromatic regions which can interact with the kinase's ATP-binding site. However, the imine linkage (N=C) may be metabolically unstable, and the thiophene ring might not optimally fit the hydrophobic pocket of GSK3-beta.\",\n    \"Limitation in Source Molecule for Property\": \"1. Metabolic instability of the imine (N=C) linkage. 2. Suboptimal hydrophobic interactions due to the thiophene ring. 3. Potential steric clashes from the piperidine ring's orientation.\",\n    \"Optimization for Source Molecule\": \"1. Replace the imine (N=C) with a more stable amide (NHC=O) to improve metabolic stability. 2. Substitute the thiophene ring with a phenyl or pyridine ring to better fit the hydrophobic pocket. 3. Consider modifying the piperidine ring to a smaller or more flexible group (e.g., dimethylamine) to reduce steric hindrance.\",\n    \"Final Target Molecule\": \"CN1CCC(c2c[nH]c3ccc(NC(=O)c4ccncc4)cc23)CC1\"\n}\n```"
    },
    {
        "src_smiles": "COc1cc(OC)c(-c2ccnc(N)n2)c(OC)c1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule is a substituted benzoxazole derivative with methoxy groups at positions 1, 3, and 5 of the benzene ring, and a 2-aminopyrimidine moiety attached at position 4. The presence of multiple methoxy groups suggests potential for hydrogen bonding and hydrophobic interactions, while the aminopyrimidine group can act as a hydrogen bond donor/acceptor.\",\n    \"Property Analysis\": \"GSK3-beta inhibitors typically require specific interactions with the ATP-binding pocket, including hydrogen bonding with key residues (e.g., Asp133, Val135) and hydrophobic interactions with the hinge region. The current structure lacks optimal hydrogen bond donors/acceptors for strong hinge binding and may have steric clashes due to the bulky methoxy groups.\",\n    \"Limitation in Source Molecule for Property\": \"1. The methoxy groups may cause steric hindrance, reducing binding affinity. 2. The aminopyrimidine moiety is not optimally positioned for hinge region interactions. 3. Lack of a strong hydrogen bond donor/acceptor pair for Asp133/Val135 interactions.\",\n    \"Optimization for Source Molecule\": \"1. Replace one methoxy group with a smaller, more flexible group (e.g., hydroxyl) to reduce steric hindrance. 2. Modify the aminopyrimidine to a more rigid bicyclic system (e.g., purine) to enhance hinge binding. 3. Introduce a hydrogen bond donor/acceptor at the meta position to interact with Asp133/Val135. 4. Consider adding a hydrophobic substituent to enhance binding in the hydrophobic pocket.\",\n    \"Final Target Molecule\": \"COc1cc(OC)c(-c2ncnc3cc(O)ccc23)c(O)c1\"\n}\n```"
    },
    {
        "src_smiles": "COc1cc2ncnc(NC(C)C)c2cc1OC",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule is a substituted quinazoline derivative with two methoxy groups at positions 1 and 4 of the benzene ring and an isopropylamino group at position 2 of the quinazoline core. The quinazoline core is a known pharmacophore for kinase inhibition, including GSK3-beta.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the methoxy groups and the secondary amine, which could aid in binding to the ATP-binding site of GSK3-beta. However, the isopropyl group may not optimally fit the hydrophobic pocket of the kinase.\",\n    \"Limitation in Source Molecule for Property\": \"The isopropyl group on the secondary amine may be too bulky, limiting optimal interactions with the hydrophobic pocket of GSK3-beta. Additionally, the methoxy groups may not provide sufficient hydrogen bonding interactions with the kinase.\",\n    \"Optimization for Source Molecule\": \"1. Replace the isopropyl group with a smaller alkyl group (e.g., methyl or ethyl) to better fit the hydrophobic pocket. 2. Introduce a hydrogen bond donor/acceptor group (e.g., hydroxyl or carbonyl) on the quinazoline core to enhance interactions with the kinase. 3. Consider replacing one methoxy group with a more polar substituent (e.g., hydroxyl or amino) to improve binding affinity.\",\n    \"Final Target Molecule\": \"COc1cc2ncnc(NC)cc2cc1OC\"\n}\n```"
    },
    {
        "src_smiles": "Nc1ccnc(Nc2ccc(Oc3ccc(Cl)cc3)cc2)c1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a central pyrimidine ring (Nc1ccnc) connected to an aniline moiety (Nc2ccc) which is further substituted with a chlorophenyl ether group (Oc3ccc(Cl)cc3). The molecule has hydrogen bond donors (NH2) and acceptors (N, O), and a hydrophobic chlorophenyl group.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the presence of NH2 and ether oxygen, which may aid in binding to GSK3-beta. However, the chlorophenyl group may contribute to off-target interactions or reduce solubility.\",\n    \"Limitation in Source Molecule for Property\": \"The primary limitation is the lack of a strong hydrogen bond acceptor/donor pair that can interact with key residues in the GSK3-beta active site (e.g., Asp133, Val135). The chlorophenyl group may also hinder optimal binding due to steric clashes or poor solubility.\",\n    \"Optimization for Source Molecule\": \"1. Replace the chlorophenyl group with a more polar substituent (e.g., pyridine or morpholine) to improve solubility and binding. 2. Introduce a sulfonamide or carboxamide group to enhance hydrogen bonding with Asp133. 3. Consider adding a small alkyl group (e.g., methyl) to the aniline ring to improve hydrophobic interactions with Val135.\",\n    \"Final Target Molecule\": \"Nc1ccnc(Nc2ccc(Oc3ccncc3)cc2)c1\"\n}\n```"
    },
    {
        "src_smiles": "c1ccc(-c2c[nH]c(-c3ccccc3)n2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a central imidazole ring (c2c[nH]cn2) connected to a phenyl ring (c1ccccc1) and another phenyl ring (c3ccccc3). The imidazole ring is a five-membered heterocycle with two nitrogen atoms, one of which is protonated ([nH]). The molecule has a planar structure due to the conjugated \u03c0-systems of the aromatic rings and the imidazole ring.\",\n    \"Property Analysis\": \"The molecule has moderate lipophilicity due to the presence of aromatic rings. The imidazole ring can act as a hydrogen bond donor and acceptor, which may contribute to interactions with the GSK3-beta enzyme. However, the molecule lacks strong electron-withdrawing or electron-donating groups, which could limit its binding affinity and specificity for GSK3-beta.\",\n    \"Limitation in Source Molecule for Property\": \"1. The molecule lacks functional groups that can form strong hydrogen bonds or electrostatic interactions with the active site of GSK3-beta. 2. The imidazole ring may not provide sufficient steric or electronic complementarity to the enzyme's binding pocket. 3. The molecule's planar structure may limit its ability to fit into the three-dimensional binding site of GSK3-beta.\",\n    \"Optimization for Source Molecule\": \"1. Introduce a sulfonamide group (-SO2NH2) to the phenyl ring to enhance hydrogen bonding with the enzyme. 2. Replace one of the phenyl rings with a pyridine ring to introduce a hydrogen bond acceptor and improve solubility. 3. Add a methyl group to the imidazole ring to increase steric complementarity with the enzyme's binding pocket. 4. Introduce a fluorine atom to the phenyl ring to enhance electronic interactions and metabolic stability.\",\n    \"Final Target Molecule\": \"c1ccc(-c2c(C)n(c(-c3cccnc3)n2)S(=O)(=O)N)cc1\"\n}\n```"
    },
    {
        "src_smiles": "c1cnc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule is a purine derivative with a piperazine ring attached to the purine core. The purine core consists of a pyrimidine ring fused with an imidazole ring, which is a common scaffold in kinase inhibitors. The piperazine ring is attached to the purine core via a nitrogen atom, providing potential for hydrogen bonding and solubility enhancement.\",\n    \"Property Analysis\": \"The molecule has moderate potential for GSK3-beta inhibition due to the purine core, which can mimic ATP and bind to the kinase domain. However, the piperazine ring may not optimally interact with the hydrophobic pocket of GSK3-beta, and the overall molecular weight and polarity may limit permeability.\",\n    \"Limitation in Source Molecule for Property\": \"The piperazine ring may not provide sufficient hydrophobic interactions with the GSK3-beta binding site. Additionally, the molecule lacks a strong hydrogen bond donor/acceptor pattern that could enhance binding affinity. The molecular weight is on the higher side, which may affect bioavailability.\",\n    \"Optimization for Source Molecule\": \"To improve GSK3-beta inhibition, the piperazine ring can be replaced with a more hydrophobic group, such as a phenyl ring, to better fit the hydrophobic pocket of GSK3-beta. Adding a hydrogen bond donor/acceptor group, such as a hydroxyl or amino group, to the purine core could enhance binding affinity. Reducing the molecular weight by simplifying the piperazine ring or replacing it with a smaller hydrophobic group could improve permeability.\",\n    \"Final Target Molecule\": \"c1cnc(-c2c[nH]c3ncnc(c23)c4ccccc4)cn1\"\n}\n```"
    },
    {
        "src_smiles": "CC(C)n1cnc2c(NCc3ccccc3)ncnc21",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a purine core (1H-imidazo[4,5-b]pyridine) with a phenylmethylamine substituent at the 2-position and an isopropyl group at the 1-position. The purine core is a common scaffold in kinase inhibitors, and the phenylmethylamine group may interact with the hinge region of GSK3-beta.\",\n    \"Property Analysis\": \"The molecule has moderate lipophilicity (logP ~2.5) and a molecular weight of 280.34 g/mol, which is within the acceptable range for kinase inhibitors. The presence of hydrogen bond donors (NH) and acceptors (N in the purine core) suggests potential for forming key interactions with GSK3-beta.\",\n    \"Limitation in Source Molecule for Property\": \"The isopropyl group at the 1-position may not optimally fill the hydrophobic pocket of GSK3-beta. The phenylmethylamine group's orientation may limit interactions with the hinge region, and the molecule lacks a strong hydrogen bond acceptor/donor pair for optimal affinity.\",\n    \"Optimization for Source Molecule\": \"1. Replace the isopropyl group with a cyclopropyl group to better fit the hydrophobic pocket. 2. Introduce a hydroxyl or fluorine substituent on the phenyl ring to enhance hinge region interactions. 3. Add a sulfonyl or carbonyl group to the phenylmethylamine to improve hydrogen bonding with the kinase.\",\n    \"Final Target Molecule\": \"CC1(C1)c1cnc2c(NCc3ccc(F)cc3)ncnc21\"\n}\n```"
    },
    {
        "src_smiles": "COc1ccc(SC)cc1CNC1CCCNC1c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a methoxy-substituted phenyl ring connected via a sulfur atom to a methyl group, and an amine-linked cyclohexyl ring with a phenyl substituent. The structure includes potential hydrogen bond donors (amine) and acceptors (methoxy, sulfur, amine).\",\n    \"Property Analysis\": \"The molecule may exhibit moderate GSK3-beta inhibition due to the presence of the amine group which can interact with the kinase's ATP-binding site. However, the methoxy and sulfur groups may not optimally contribute to binding affinity or selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy group may not provide strong electrostatic interactions with the target. The sulfur atom's lone pairs might not be optimally positioned for hydrogen bonding. The flexibility of the cyclohexyl ring could reduce binding specificity.\",\n    \"Optimization for Source Molecule\": \"Replace the methoxy group with a more polar group like a hydroxyl or a carbonyl-containing group to enhance hydrogen bonding. Substitute the sulfur with a nitrogen atom to improve hydrogen bond acceptor capability. Rigidify the cyclohexyl ring by introducing double bonds or aromaticity to reduce conformational flexibility and improve binding specificity.\",\n    \"Final Target Molecule\": \"O=C1CCC(NC2CCNC2c2ccccc2)N1c1ccc(O)cc1\"\n}\n```"
    },
    {
        "src_smiles": "c1ccc(Cn2cc(CSc3nnc(C4CCCC4)o3)nn2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a phenyl ring connected to a triazole ring via a methylene linker. The triazole ring is further substituted with a thioether-linked oxadiazole ring, which is connected to a cyclopentyl group. The structure suggests potential for hydrogen bonding and hydrophobic interactions.\",\n    \"Property Analysis\": \"The molecule has moderate hydrophobicity due to the phenyl and cyclopentyl groups. The triazole and oxadiazole rings may engage in hydrogen bonding, but the overall polarity might be limited by the thioether linkage.\",\n    \"Limitation in Source Molecule for Property\": \"The thioether linkage may reduce the molecule's ability to form strong hydrogen bonds with GSK3-beta. The cyclopentyl group, while hydrophobic, may not optimally fit the binding pocket. The methylene linker between the phenyl and triazole rings might restrict conformational flexibility.\",\n    \"Optimization for Source Molecule\": \"Replace the thioether linkage with a more polar group like an amide or ether to enhance hydrogen bonding. Introduce a more rigid or polar group in place of the cyclopentyl ring to better fit the binding pocket. Consider shortening or rigidifying the methylene linker to improve conformational stability.\",\n    \"Final Target Molecule\": \"c1ccc(Cn2cc(COc3nnc(C4CCNCC4)o3)nn2)cc1\"\n}\n```"
    },
    {
        "src_smiles": "Cc1cc2[nH]ncc2cc1-c1ccccc1C(F)(F)F",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a trifluoromethylphenyl group attached to a benzimidazole core, which is further substituted with a methyl group. The benzimidazole core is a known pharmacophore for kinase inhibition, and the trifluoromethyl group can enhance binding affinity through hydrophobic interactions.\",\n    \"Property Analysis\": \"The benzimidazole core is likely to interact with the ATP-binding site of GSK3-beta, but the current structure may lack optimal hydrogen bonding or electrostatic interactions for strong inhibition. The trifluoromethyl group provides hydrophobicity but may not contribute significantly to binding specificity.\",\n    \"Limitation in Source Molecule for Property\": \"The molecule lacks hydrogen bond donors or acceptors that could form critical interactions with the kinase's hinge region or other key residues. The methyl group on the benzimidazole may not provide sufficient steric or electronic effects to enhance binding.\",\n    \"Optimization for Source Molecule\": \"1. Introduce a hydrogen bond donor/acceptor (e.g., NH2, OH, or carbonyl) on the benzimidazole core to interact with the hinge region. 2. Replace the methyl group with a bulkier or more polar substituent to improve steric or electronic effects. 3. Modify the trifluoromethylphenyl group to include a polar or charged group (e.g., sulfonamide or pyridine) for additional interactions.\",\n    \"Final Target Molecule\": \"Cc1cc2[nH]nc(N)c2cc1-c1ccccc1C(F)(F)F\"\n}\n```"
    },
    {
        "src_smiles": "c1ccc2c(N3CCCCCC3)nc(-c3ccncc3)nc2c1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a quinazoline core (c1ccc2c(N3CCCCCC3)nc(-c3ccncc3)nc2c1) with a piperidine ring (N3CCCCCC3) attached to the nitrogen at position 2 and a pyridine ring (c3ccncc3) attached to the carbon at position 4. The quinazoline core is a known pharmacophore for kinase inhibition, including GSK3-beta.\",\n    \"Property Analysis\": \"The quinazoline core provides a good starting point for GSK3-beta inhibition due to its ability to bind to the ATP-binding site. The piperidine ring may contribute to solubility and bioavailability, while the pyridine ring could engage in additional interactions with the kinase.\",\n    \"Limitation in Source Molecule for Property\": \"The piperidine ring is quite flexible and may not optimally fit the binding pocket. The pyridine ring's position and orientation may not maximize interactions with the kinase. Additionally, the molecule lacks hydrogen bond donors or acceptors that could enhance binding affinity.\",\n    \"Optimization for Source Molecule\": \"1. Replace the piperidine ring with a more rigid and polar group, such as a morpholine ring, to improve binding and solubility. 2. Introduce a hydrogen bond donor or acceptor on the pyridine ring to enhance interactions with the kinase. 3. Consider adding a small hydrophobic group to the quinazoline core to fill a hydrophobic pocket in the binding site.\",\n    \"Final Target Molecule\": \"c1ccc2c(N3CCOCC3)nc(-c3ccnc(N)c3)nc2c1\"\n}\n```"
    },
    {
        "src_smiles": "COc1ccc(-c2nnc(SCC#N)o2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a methoxy-substituted phenyl ring connected to a thiazole ring with a cyanoethylthio substituent. The thiazole ring is a known pharmacophore for kinase inhibition, and the phenyl ring can contribute to binding affinity through pi-pi interactions.\",\n    \"Property Analysis\": \"The molecule has moderate potential for GSK3-beta inhibition due to the presence of the thiazole ring, which can interact with the ATP-binding site. However, the cyanoethylthio group may not optimally interact with the kinase's hydrophobic pocket or hinge region.\",\n    \"Limitation in Source Molecule for Property\": \"The cyanoethylthio group is too flexible and may not provide optimal hydrophobic interactions or hydrogen bonding with the kinase. Additionally, the methoxy group on the phenyl ring may not sufficiently enhance binding affinity or selectivity.\",\n    \"Optimization for Source Molecule\": \"Replace the cyanoethylthio group with a more rigid and hydrophobic substituent, such as a phenyl or cyclopropyl group, to better fit the hydrophobic pocket. Consider adding a hydrogen bond donor or acceptor to the phenyl ring (e.g., hydroxyl or amino group) to enhance interactions with the hinge region or other key residues.\",\n    \"Final Target Molecule\": \"COc1ccc(-c2nnc(SCC#N)o2)cc1\"\n}\n```"
    },
    {
        "src_smiles": "Cn1ccc(Oc2ccc3cc(NC(=O)C4CC4)ncc3c2)n1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyridine ring (n1ccc) connected to a phenyl ring (c2ccc) via an oxygen linker (O). The phenyl ring is further substituted with a pyrimidine-like ring (c3ccncc3) and an amide group (NC(=O)C4CC4). The molecule has moderate flexibility due to the cyclopropyl ring in the amide moiety.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the presence of hydrogen bond donors (amide NH) and acceptors (carbonyl O, pyridine N, ether O), which can interact with the kinase's ATP-binding site. The aromatic systems may engage in pi-pi stacking with key residues.\",\n    \"Limitation in Source Molecule for Property\": \"1) The cyclopropyl ring may limit optimal binding conformation due to steric constraints. 2) The ether linkage (Oc2ccc) may reduce metabolic stability. 3) Lack of strong electron-withdrawing groups near the pyridine N could weaken key interactions with the kinase's hinge region.\",\n    \"Optimization for Source Molecule\": \"1) Replace cyclopropyl with a more flexible/planar group (e.g., cyclobutyl or phenyl) to improve binding pocket accommodation. 2) Substitute the ether oxygen with a more rigid linker (e.g., direct C-C bond or amide). 3) Introduce a fluorine or nitro group ortho to the pyridine N to enhance hinge binding. 4) Consider adding a sulfonamide group to increase hydrogen bonding with the kinase's Lys85 residue.\",\n    \"Final Target Molecule\": \"Cn1ccc(C2ccc3cc(NC(=O)c4ccc(F)cc4)ncc3c2)n1\"\n}\n```"
    },
    {
        "src_smiles": "OCc1cccc(Nc2nc(-c3cccnc3)nc3ccccc23)c1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a phenol group (OCc1cccc), a central aniline (Nc2nc), a pyrimidine ring (-c2nc3ccccc23), and a pyridine ring (-c3cccnc3). The molecule has potential hydrogen bond donors (OH and NH) and acceptors (N in pyrimidine and pyridine).\",\n    \"Property Analysis\": \"GSK3-beta inhibitors often require specific interactions with the ATP-binding site, including hydrogen bonding with key residues (e.g., Asp133, Val135) and hydrophobic interactions. The current molecule may lack optimal steric and electronic features for strong inhibition.\",\n    \"Limitation in Source Molecule for Property\": \"1. The phenol group may not provide optimal hydrogen bonding or hydrophobic interactions. 2. The pyridine ring's basic nitrogen could lead to undesired protonation states. 3. The aniline linker may not position the pyrimidine and pyridine rings optimally for binding.\",\n    \"Optimization for Source Molecule\": \"1. Replace the phenol with a more potent hydrogen bond donor/acceptor (e.g., sulfonamide or amide). 2. Modify the pyridine to a less basic heterocycle (e.g., pyridazine or pyrimidine). 3. Introduce a methyl or halogen at the pyrimidine ring to enhance hydrophobic interactions. 4. Shorten the aniline linker or rigidify it with a cyclopropyl group to improve binding pose.\",\n    \"Final Target Molecule\": \"O=C(Nc1cccc(Nc2nc(-c3ccncc3)nc3ccccc23)c1)C\"\n}\n```"
    },
    {
        "src_smiles": "Cn1nc(C(N)=O)c2c1-c1nc(NCc3ccccc3)ncc1CC2",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a purine-like core with a benzimidazole moiety and a phenyl group attached via an aminoethyl linker. The structure includes hydrogen bond donors (N-H) and acceptors (C=O, N in the ring), which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule has moderate hydrogen bonding capacity and lipophilicity, but the phenyl group may not optimally interact with the hydrophobic pocket of GSK3-beta. The aminoethyl linker might also limit the molecule's conformational flexibility.\",\n    \"Limitation in Source Molecule for Property\": \"The phenyl group may not provide optimal hydrophobic interactions with the target. The aminoethyl linker could restrict the molecule's ability to adopt the preferred conformation for binding. The hydrogen bond acceptor/donor pattern may not fully match the GSK3-beta active site requirements.\",\n    \"Optimization for Source Molecule\": \"1. Replace the phenyl group with a more hydrophobic and bulky group (e.g., naphthyl or biphenyl) to enhance hydrophobic interactions. 2. Modify the aminoethyl linker to a more flexible or constrained linker (e.g., propyl or cyclopropyl) to improve binding conformation. 3. Introduce additional hydrogen bond donors/acceptors (e.g., hydroxyl or carbonyl groups) to better match the GSK3-beta active site.\",\n    \"Final Target Molecule\": \"Cn1nc(C(N)=O)c2c1-c1nc(NC(C)Cc3ccccc3)ncc1CC2\"\n}\n```"
    },
    {
        "src_smiles": "Cc1sc2ncnc(NCCCO)c2c1C",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a thiazole ring (sc2) fused with a pyrimidine ring (ncnc), an aminoethyl side chain (NCCCO), and a methyl group (Cc1). The molecule has potential hydrogen bond donors (NH) and acceptors (N in the rings).\",\n    \"Property Analysis\": \"The molecule may exhibit moderate GSK3-beta inhibition due to the presence of nitrogen-containing heterocycles, which can interact with the ATP-binding site of GSK3-beta. However, the inhibition may be limited by the flexibility of the side chain and lack of optimal hydrophobic interactions.\",\n    \"Limitation in Source Molecule for Property\": \"The aminoethyl side chain (NCCCO) is too flexible and may not provide optimal binding affinity. The methyl group (Cc1) may not contribute significantly to hydrophobic interactions. The molecule may also lack sufficient aromatic or planar regions for strong binding.\",\n    \"Optimization for Source Molecule\": \"1. Replace the flexible aminoethyl side chain with a more rigid aromatic or heteroaromatic group to enhance binding affinity. 2. Introduce a bulkier hydrophobic group instead of the methyl group to improve hydrophobic interactions. 3. Consider adding a carbonyl or sulfonyl group to increase hydrogen bonding potential with the kinase.\",\n    \"Final Target Molecule\": \"Cc1sc2ncnc(Nc3ccccc3)c2c1C(=O)O\"\n}\n```"
    },
    {
        "src_smiles": "CCNc1nc2cc(Cl)c(C#CCCCC#N)cc2nc1NCC",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a pyrimidine core (c1nc2cc(Cl)c(C#CCCCC#N)cc2nc1) with a chlorine substituent and an extended alkyne chain (C#CCCCC#N) attached. It also has ethylamino (CCN) and aminomethyl (NCC) substituents on the pyrimidine nitrogen atoms.\",\n    \"Property Analysis\": \"The molecule has potential for GSK3-beta inhibition due to the presence of hydrogen bond donors (NH groups) and acceptors (nitrogen atoms in the pyrimidine and nitrile). The alkyne chain may contribute to hydrophobic interactions, but its length and linearity might limit optimal binding.\",\n    \"Limitation in Source Molecule for Property\": \"The long, linear alkyne chain (C#CCCCC#N) may not optimally fit the binding pocket of GSK3-beta, potentially reducing binding affinity. The chlorine substituent might not contribute significantly to binding and could be replaced with more favorable groups.\",\n    \"Optimization for Source Molecule\": \"1. Replace the alkyne chain with a more compact hydrophobic group (e.g., phenyl or cyclohexyl) to improve binding pocket fit. 2. Replace the chlorine with a hydrogen bond acceptor (e.g., methoxy or amino group) to enhance interactions with the target. 3. Consider modifying the ethylamino group to a cyclopropylamino group to increase rigidity and potentially improve binding.\",\n    \"Final Target Molecule\": \"CCNc1nc2cc(OC)c(C3CC3)cc2nc1NCC\"\n}\n```"
    },
    {
        "src_smiles": "c1ccc(Cn2c(-c3ccccc3)nc3ccccc32)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a central imidazole ring (with nitrogen atoms at positions 1 and 3) fused to two benzene rings, forming a benzimidazole core. A phenyl group is attached to the 2-position of the imidazole, and a benzyl group is attached to the nitrogen at position 1. The molecule has a planar benzimidazole core with potential for \u03c0-\u03c0 stacking interactions.\",\n    \"Property Analysis\": \"The benzimidazole core is a known pharmacophore for kinase inhibition, including GSK3-beta. The phenyl and benzyl substituents may contribute to hydrophobic interactions but could limit solubility and binding affinity. The molecule lacks hydrogen bond donors/acceptors, which are often important for kinase inhibition.\",\n    \"Limitation in Source Molecule for Property\": \"1. Lack of hydrogen bond donors/acceptors to form critical interactions with the kinase hinge region. 2. The benzyl group may cause steric hindrance or suboptimal positioning. 3. Limited solubility due to high hydrophobicity. 4. No groups to target the phosphate-binding region of GSK3-beta.\",\n    \"Optimization for Source Molecule\": \"1. Introduce a hydrogen bond donor/acceptor at the 5-position of the benzimidazole to target the hinge region (e.g., NH2 or OH). 2. Replace the benzyl group with a more polar group to improve solubility and binding (e.g., pyridylmethyl). 3. Add a small polar group (e.g., morpholine) to the phenyl ring at position 2 to target the phosphate-binding region. 4. Consider fluorination to improve metabolic stability.\",\n    \"Final Target Molecule\": \"COc1ccc(Cn2c(-c3ccc(OCCO)cc3)nc3cc(N)cc32)cc1\"\n}\n```"
    },
    {
        "src_smiles": "COc1ccc2nc(NC(=O)CSc3ccccc3)sc2c1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a benzothiazole core (c1ccc2nc(NC(=O)CSc3ccccc3)sc2c1) with a methoxy group (COc1) and a phenylthioacetamide substituent (NC(=O)CSc3ccccc3) attached to the benzothiazole nitrogen. The benzothiazole scaffold is known to interact with the ATP-binding site of GSK3-beta, while the phenylthioacetamide moiety may contribute to binding affinity but could be optimized for better interactions.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the benzothiazole core, which can mimic ATP and bind to the kinase domain. However, the methoxy group may not contribute significantly to binding affinity or selectivity. The phenylthioacetamide group could be modified to enhance hydrogen bonding or hydrophobic interactions with the target.\",\n    \"Limitation in Source Molecule for Property\": \"1. The methoxy group may not optimally interact with the target. 2. The phenylthioacetamide group lacks strong hydrogen bond donors/acceptors for enhanced binding. 3. The thioether linkage (C-S-C) may limit conformational flexibility or metabolic stability.\",\n    \"Optimization for Source Molecule\": \"1. Replace the methoxy group with a more polar or hydrogen-bonding group (e.g., hydroxyl or amino). 2. Modify the phenylthioacetamide to include hydrogen bond donors/acceptors (e.g., replace phenyl with pyridine or add a carboxylate). 3. Replace the thioether with a more stable or flexible linker (e.g., methylene or ethylene). 4. Introduce a basic nitrogen (e.g., piperazine) to enhance solubility and binding.\",\n    \"Final Target Molecule\": \"COc1ccc2nc(NC(=O)CCc3ccccc3)sc2c1\"\n}\n```"
    },
    {
        "src_smiles": "c1ccc(-c2nc(-c3ccccc3)c(-c3ccccc3)[nH]2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a central imidazole ring (with NH group) connected to two phenyl rings and a third phenyl ring attached via a single bond. The structure has aromatic character and potential for hydrogen bonding due to the NH group.\",\n    \"Property Analysis\": \"GSK3-beta inhibitors often require specific interactions with the ATP-binding pocket, including hydrogen bonding with key residues (e.g., Asp133, Val135) and hydrophobic interactions. The current structure lacks optimal hydrogen bond donors/acceptors and may have limited hydrophobic complementarity.\",\n    \"Limitation in Source Molecule for Property\": \"1) Limited hydrogen bonding capacity (only one NH group). 2) Bulky phenyl rings may cause steric clashes. 3) Lack of polar groups for optimal interactions with the kinase hinge region. 4) No charged groups for ionic interactions.\",\n    \"Optimization for Source Molecule\": \"1) Introduce a hydrogen bond acceptor/donor pair (e.g., carbonyl + NH) to mimic ATP's adenine interactions. 2) Replace one phenyl ring with a smaller hydrophobic group (e.g., methyl). 3) Add a basic nitrogen for salt bridge formation with Asp133. 4) Incorporate a sulfonamide or amide group for additional hinge binding.\",\n    \"Final Target Molecule\": \"COc1ccc(-c2nc(-c3ccccc3)c(=O)[nH]2)cc1\"\n}\n```"
    },
    {
        "src_smiles": "COc1n[nH]c2cc(NC(=O)NC(C)c3ccc(F)cc3)ncc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a benzimidazole core with a fluorophenyl group attached via a urea linkage. The benzimidazole is substituted with a methoxy group and an additional nitrogen in the ring system.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the presence of the urea moiety, which can act as a hydrogen bond donor/acceptor, and the fluorophenyl group, which can contribute to binding affinity through hydrophobic interactions.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy group may not optimally contribute to binding affinity or selectivity for GSK3-beta. The urea linkage, while beneficial, might be suboptimal for potency due to conformational flexibility.\",\n    \"Optimization for Source Molecule\": \"Replace the methoxy group with a more polar or hydrogen-bonding group like a hydroxyl or amine to enhance binding interactions. Consider rigidifying the urea linkage by incorporating it into a heterocyclic ring to reduce flexibility and improve potency. Introduce additional hydrophobic or aromatic groups to enhance binding in the hydrophobic pockets of GSK3-beta.\",\n    \"Final Target Molecule\": \"Oc1n[nH]c2cc(NC(=O)N1C(C)c3ccc(F)cc3)ncc12\"\n}\n```"
    },
    {
        "src_smiles": "COc1ccc(C(=O)OCC(=O)NCc2ccco2)cc1OC",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central amide linkage (-NC(=O)-) connecting a phenyl ring (substituted with two methoxy groups) and a furan ring. The ester group (-COO-) is attached to the phenyl ring. The molecule has moderate polarity due to the presence of amide, ester, and ether functionalities.\",\n    \"Property Analysis\": \"GSK3-beta inhibitors typically require specific interactions with the ATP-binding site, including hydrogen bonding with key residues (e.g., Asp133, Val135) and hydrophobic interactions. The current structure lacks optimal hydrogen bond donors/acceptors and may have suboptimal steric fit.\",\n    \"Limitation in Source Molecule for Property\": \"1. The ester group may lead to metabolic instability. 2. The amide linker's conformation may not optimally position the aromatic rings for binding. 3. Lack of strong hydrogen bond donors for key interactions with Asp133. 4. The furan ring may not provide sufficient hydrophobic interactions.\",\n    \"Optimization for Source Molecule\": \"1. Replace ester with a more stable amide or heterocycle. 2. Introduce a hydrogen bond donor (e.g., NH) near the amide linker. 3. Replace furan with a bulkier aromatic group (e.g., indole) for better hydrophobic packing. 4. Add a basic nitrogen (e.g., piperazine) to interact with the hinge region. 5. Constrain the amide linker conformation with a ring system.\",\n    \"Final Target Molecule\": \"COc1ccc(C(=O)N2CCN(Cc3ccco3)CC2)cc1OC\"\n}\n```"
    },
    {
        "src_smiles": "O=C1NC(=O)C(=Cc2ccc(O)cc2)N1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a hydantoin core (O=C1NC(=O)C=N1) with a substituted phenyl ring (c2ccc(O)cc2) attached via a double bond. The hydantoin core is a known pharmacophore for kinase inhibition, and the phenolic group may contribute to hydrogen bonding interactions.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the hydantoin core, which can mimic ATP's adenine binding. However, the lack of additional hydrogen bond acceptors/donors and hydrophobic groups may limit its binding affinity and selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"1. Limited hydrogen bonding capacity beyond the hydantoin core. 2. The phenyl ring lacks substituents to enhance hydrophobic interactions with the kinase's binding pocket. 3. No basic nitrogen for salt bridge formation with Asp133 in GSK3-beta.\",\n    \"Optimization for Source Molecule\": \"1. Introduce a basic nitrogen (e.g., piperazine or morpholine) to interact with Asp133. 2. Add hydrophobic substituents (e.g., methyl, chloro) to the phenyl ring for enhanced binding. 3. Extend the hydantoin core with a hydrogen bond donor/acceptor (e.g., NH2 or OH) to improve interactions with the kinase backbone.\",\n    \"Final Target Molecule\": \"O=C1NC(=O)C(=Cc2ccc(O)c(Cl)c2)N1CN3CCOCC3\"\n}\n```"
    },
    {
        "src_smiles": "CC(CO)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrazolo[3,4-b]pyridine core with a phenyl ring attached via an amide linkage. It also has a diol side chain (CC(CO)CO-) attached to the pyrazolo[3,4-b]pyridine nitrogen. The molecule has hydrogen bond donors (NH of pyrazole and urea) and acceptors (carbonyl oxygen and pyridine nitrogen).\",\n    \"Property Analysis\": \"GSK3-beta inhibitors typically require specific interactions with the ATP-binding site, including hydrogen bonding with backbone residues and hydrophobic interactions in the pocket. The current molecule has some features that could interact with GSK3-beta but may lack optimal binding affinity and selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"1) The diol side chain may be too flexible, reducing binding affinity. 2) The urea linkage, while providing H-bonding, may not optimally position the phenyl ring in the hydrophobic pocket. 3) The pyrazolo[3,4-b]pyridine core, while a good scaffold, may benefit from additional substitutions to enhance interactions.\",\n    \"Optimization for Source Molecule\": \"1) Replace the flexible diol side chain with a more rigid, aromatic group to enhance hydrophobic interactions. 2) Modify the urea linkage to a more constrained amide or heterocycle to better position the phenyl ring. 3) Introduce a small hydrophobic group at the 5-position of the pyrazolo[3,4-b]pyridine core to fill a subpocket in GSK3-beta.\",\n    \"Final Target Molecule\": \"CC(=O)Nc1n[nH]c2cc(NC(=O)c3ccc(C)cc3)ncc12\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccc3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring fused with an imidazole ring (purine-like core), substituted with a phenyl group, a urea linkage, and a benzyloxy group. The molecule has moderate flexibility due to the presence of rotatable bonds in the urea and benzyloxy moieties.\",\n    \"Property Analysis\": \"The molecule may exhibit moderate GSK3-beta inhibition due to the purine-like core, which can mimic ATP binding. However, the benzyloxy group may not optimally interact with the hydrophobic pocket of GSK3-beta, and the urea linkage might limit solubility or binding affinity.\",\n    \"Limitation in Source Molecule for Property\": \"1. The benzyloxy group may not optimally fill the hydrophobic pocket of GSK3-beta. 2. The urea linkage could reduce membrane permeability or solubility. 3. Lack of strong hydrogen bond donors/acceptors for key interactions with the kinase.\",\n    \"Optimization for Source Molecule\": \"1. Replace the benzyloxy group with a more rigid and hydrophobic group (e.g., naphthyl or biphenyl) to better fit the hydrophobic pocket. 2. Replace the urea linkage with an amide or sulfonamide to improve solubility and binding. 3. Introduce a hydrogen bond donor (e.g., NH or OH) at the 2-position of the purine core to enhance interactions with the hinge region of GSK3-beta.\",\n    \"Final Target Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(Oc3ccc(cc3)-c4ccccc4)c2cn1)c1ccccc1\"\n}\n```"
    },
    {
        "src_smiles": "CC(c1ccncc1)c1nnc(Nc2ccc(Cl)cc2)c2ccccc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrazole ring (c1nnc) connected to a phenyl ring (c2ccccc12) and a chlorophenyl group (Nc2ccc(Cl)cc2). It also has a methyl-substituted pyridine (CC(c1ccncc1)) attached to the pyrazole ring. The molecule has moderate flexibility due to the single bonds connecting the aromatic rings.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the presence of aromatic rings and hydrogen bond acceptors (nitrogen atoms in pyrazole and pyridine). However, the inhibition may be suboptimal due to steric hindrance from the bulky groups and lack of strong hydrogen bond donors.\",\n    \"Limitation in Source Molecule for Property\": \"1. The methyl group on the pyridine may cause steric hindrance, reducing binding affinity. 2. Lack of strong hydrogen bond donors limits interactions with the kinase. 3. The chlorophenyl group may not optimally fit the hydrophobic pocket of GSK3-beta.\",\n    \"Optimization for Source Molecule\": \"1. Replace the methyl group on the pyridine with a smaller hydrogen to reduce steric hindrance. 2. Introduce a hydrogen bond donor (e.g., NH2) on the pyrazole ring to enhance interactions with the kinase. 3. Replace the chlorophenyl group with a more polar group (e.g., pyrimidine) to better fit the hydrophobic pocket and provide additional hydrogen bonding.\",\n    \"Final Target Molecule\": \"O=C(Nc1nccn1)c1nnc(Nc2ccc(N)cc2)c2ccccc12\"\n}\n```"
    },
    {
        "src_smiles": "CCC(O)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrazolo[1,5-a]pyrimidine core with a phenyl ring substitution at position 7, an amide linkage to a secondary amine, and an ethoxyethanol side chain at position 2. The molecule has moderate flexibility due to the ethoxyethanol side chain and the amide linkage.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the presence of the pyrazolo[1,5-a]pyrimidine core, which can act as a hinge binder, and the secondary amide which can form hydrogen bonds with the kinase. However, the ethoxyethanol side chain may not optimally interact with the hydrophobic pocket of GSK3-beta.\",\n    \"Limitation in Source Molecule for Property\": \"The ethoxyethanol side chain is too flexible and polar, which may reduce binding affinity and selectivity for GSK3-beta. The secondary amide, while capable of hydrogen bonding, may not provide optimal interactions with the kinase's active site.\",\n    \"Optimization for Source Molecule\": \"1. Replace the ethoxyethanol side chain with a more rigid and hydrophobic group (e.g., phenyl or cyclopentyl) to better fit the hydrophobic pocket of GSK3-beta. 2. Modify the secondary amide to a tertiary amide or urea to enhance hydrogen bonding with the kinase. 3. Introduce a fluorine atom on the phenyl ring to improve binding affinity through hydrophobic interactions and potential halogen bonding.\",\n    \"Final Target Molecule\": \"CC1(C(=O)NC2=NC=C3C(=N2)N(N=C3C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=C(C=C6)F\"\n}\n```"
    },
    {
        "src_smiles": "COc1ccccc1-c1ccc(CC(NC(=O)Cn2cnnn2)C(=O)O)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a biphenyl core with a methoxy group on one phenyl ring and a substituted phenyl ring on the other. The substitution includes a carboxylic acid group, an amide linkage, and a triazole ring. The molecule has moderate flexibility due to the presence of the -CH2- linker and the amide bond.\",\n    \"Property Analysis\": \"The molecule has potential for GSK3-beta inhibition due to the presence of hydrogen bond donors (amide NH) and acceptors (carboxylic acid, amide C=O, triazole N). However, the methoxy group may not contribute significantly to binding affinity.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy group is not optimal for GSK3-beta inhibition as it lacks strong hydrogen bonding capability. The carboxylic acid may limit cell permeability. The triazole ring, while a good hydrogen bond acceptor, may not optimally fit the active site.\",\n    \"Optimization for Source Molecule\": \"1. Replace the methoxy group with a more polar group like a hydroxyl or amino group to enhance hydrogen bonding. 2. Consider replacing the carboxylic acid with a bioisostere like a tetrazole or sulfonamide to improve permeability while maintaining hydrogen bonding. 3. Modify the triazole ring to a more rigid heterocycle like oxadiazole to better fit the active site.\",\n    \"Final Target Molecule\": \"Oc1ccccc1-c1ccc(CC(NC(=O)Cn2cncn2)C(=O)N)cc1\"\n}\n```"
    },
    {
        "src_smiles": "Brc1cnc(N2CCOCC2)nc1Nc1cc(C2CC2)[nH]n1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a bromo-substituted pyrimidine core linked to a morpholine ring via a nitrogen atom, and a hydrazinyl-substituted pyrazole ring with a cyclopropyl group. The presence of bromine and the morpholine ring suggests potential for interactions with GSK3-beta, but the overall structure may lack optimal binding affinity and selectivity.\",\n    \"Property Analysis\": \"The molecule shows moderate GSK3-beta inhibition potential due to the pyrimidine core and morpholine ring, which can interact with the ATP-binding site. However, the bromine atom may not contribute significantly to binding, and the hydrazinyl-pyrazole moiety might introduce metabolic instability.\",\n    \"Limitation in Source Molecule for Property\": \"1. Bromine substitution may not enhance binding affinity. 2. Hydrazinyl group in the pyrazole ring could lead to metabolic instability. 3. Cyclopropyl group may not optimally fit the hydrophobic pocket of GSK3-beta.\",\n    \"Optimization for Source Molecule\": \"1. Replace bromine with a more polar group (e.g., hydroxyl or amino) to enhance hydrogen bonding with the kinase. 2. Modify the hydrazinyl group to a more stable amide or urea linkage. 3. Replace cyclopropyl with a bulkier hydrophobic group (e.g., phenyl or tert-butyl) to better occupy the hydrophobic pocket. 4. Introduce a fluorine atom on the pyrimidine core to improve binding affinity and metabolic stability.\",\n    \"Final Target Molecule\": \"Oc1cnc(N2CCOCC2)nc1Nc1cc(C2CC2)n(C(=O)N)n1\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccc3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring (c1cc2[nH]nc(OCc3ccccc3)c2cn1) with an attached phenyl group (c1ccccc1) and a urea linkage (NC(=O)N) connected to an isopropylamine group (CC(N)). The molecule also has a benzyloxy substituent (OCc3ccccc3) on the pyrimidine ring.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the presence of the pyrimidine core, which is a common scaffold in kinase inhibitors. The urea linkage may contribute to hydrogen bonding with the kinase, and the aromatic rings could provide hydrophobic interactions.\",\n    \"Limitation in Source Molecule for Property\": \"The isopropylamine group may not optimally interact with the kinase's binding site, and the benzyloxy substituent might be too bulky, potentially reducing binding affinity or selectivity. The urea linkage, while capable of hydrogen bonding, may not be the most optimal for strong interactions with the kinase's active site.\",\n    \"Optimization for Source Molecule\": \"1. Replace the isopropylamine group with a more polar or hydrogen-bonding group, such as a piperazine or morpholine ring, to enhance interactions with the kinase. 2. Modify the benzyloxy substituent to a smaller or more flexible group, such as a methoxy or ethoxy group, to reduce steric hindrance. 3. Replace the urea linkage with a more potent hydrogen-bonding group, such as a sulfonamide or amide, to improve binding affinity.\",\n    \"Final Target Molecule\": \"CC1CCN(C(=O)Nc2cc3[nH]nc(OCC)c3cn2)CC1\"\n}\n```"
    },
    {
        "src_smiles": "CC(CCn1ccc(-c2ccc(F)cc2)cc1=O)(C(=O)NO)S(C)(=O)=O",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a sulfonyl group (S(=O)(=O)), a ketone (C=O), a nitroso group (C(=O)NO), and a fluorinated phenyl ring. The presence of these functional groups suggests potential interactions with the GSK3-beta active site, particularly the sulfonyl and ketone groups which can form hydrogen bonds.\",\n    \"Property Analysis\": \"The molecule shows moderate potential for GSK3-beta inhibition due to its ability to form hydrogen bonds and hydrophobic interactions. However, the nitroso group may introduce instability or toxicity, and the sulfonyl group might be too polar, affecting bioavailability.\",\n    \"Limitation in Source Molecule for Property\": \"The nitroso group (C(=O)NO) is a potential limitation due to its instability and potential toxicity. The sulfonyl group (S(=O)(=O)) may also be too polar, reducing cell permeability. The fluorinated phenyl ring, while providing hydrophobic interactions, may not be optimal for binding affinity.\",\n    \"Optimization for Source Molecule\": \"Replace the nitroso group with a more stable and less toxic amide group (CONH2) to improve stability and reduce toxicity. Modify the sulfonyl group to a sulfonamide (SO2NH2) to balance polarity and improve binding affinity. Introduce a heterocyclic ring (e.g., pyridine) in place of the fluorinated phenyl ring to enhance binding interactions with the kinase active site.\",\n    \"Final Target Molecule\": \"CC(CCn1ccc(-c2cccnc2)cc1=O)(C(=O)NH2)S(=O)(=O)NH\"\n}\n```"
    },
    {
        "src_smiles": "COCCSc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a benzimidazole core (c1n[nH]c2ccncc12) with a methylsulfanyl (SMe) substituent and a phenyl ring attached via a urea linkage (NC(=O)NC(C)c3ccccc3). The benzimidazole core is a common pharmacophore in kinase inhibitors, and the urea moiety can engage in hydrogen bonding interactions with the kinase.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the benzimidazole core, which can interact with the ATP-binding site. The urea linkage may form hydrogen bonds with the hinge region of the kinase. However, the methylsulfanyl group might not contribute significantly to binding and could be optimized for better interactions.\",\n    \"Limitation in Source Molecule for Property\": \"The methylsulfanyl (SMe) group is a potential metabolic liability and may not provide optimal interactions with the kinase. The urea linkage, while capable of hydrogen bonding, may be suboptimal for potency or selectivity. The phenyl ring lacks substituents that could enhance binding affinity or selectivity.\",\n    \"Optimization for Source Molecule\": \"1. Replace the methylsulfanyl (SMe) group with a more polar or hydrogen-bonding group like a hydroxyl or amine to improve interactions with the kinase. 2. Modify the urea linkage to a more rigid or potent bioisostere, such as a pyrazole or triazole, to enhance binding affinity. 3. Introduce electron-withdrawing or donating groups on the phenyl ring to modulate the electronic properties and improve binding or selectivity.\",\n    \"Final Target Molecule\": \"COCC1=NNC2=CC(NC(=O)N3C=C(C)C=C3C4=CC=CC=C4)=NC=C12\"\n}\n```"
    },
    {
        "src_smiles": "COCCOc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a methoxyethyl ether group (COCCO), a pyrazole ring (n[nH]c2cc), and a phenyl ring (c3ccccc3) connected via a urea linkage (NC(=O)NC). The pyrazole ring is fused with a pyrimidine ring (ncc12), and the phenyl ring is substituted with a methyl group (C(C)).\",\n    \"Property Analysis\": \"The molecule has potential for GSK3-beta inhibition due to the presence of the urea linkage, which can form hydrogen bonds with the kinase, and the aromatic rings, which can participate in pi-pi stacking interactions. However, the methoxyethyl ether group may reduce binding affinity due to its flexibility and lack of strong interactions with the target.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxyethyl ether group (COCCO) is flexible and may not contribute significantly to binding affinity. The methyl substitution on the phenyl ring (C(C)) may also limit interactions with the kinase.\",\n    \"Optimization for Source Molecule\": \"Replace the methoxyethyl ether group with a more rigid and polar group, such as a morpholine ring, to enhance binding affinity. Introduce a halogen (e.g., fluorine) on the phenyl ring to improve interactions with the kinase. The urea linkage can be retained or modified to a more stable amide or sulfonamide group.\",\n    \"Final Target Molecule\": \"COC1CNCCN1c1n[nH]c2cc(NC(=O)NC(C)c3cc(F)ccc3)ncc12\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring (c1cc2[nH]nc(CNCC(F)F)c2cn1) with an amide linkage (NC(=O)N) to a phenyl ring (c1ccccc1) and a difluoroethylamine side chain (CNCC(F)F). The pyrimidine ring is a key scaffold known for kinase inhibition, and the phenyl ring may contribute to hydrophobic interactions.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the pyrimidine core, which can mimic ATP binding. The difluoroethylamine side chain may enhance binding through polar interactions, but the amide linkage could limit conformational flexibility and reduce potency.\",\n    \"Limitation in Source Molecule for Property\": \"The amide linkage (NC(=O)N) may restrict conformational flexibility, reducing optimal binding to GSK3-beta. The difluoroethylamine side chain (CNCC(F)F) might not optimally fit the hydrophobic pocket of the kinase, and the phenyl ring (c1ccccc1) could be too bulky for efficient binding.\",\n    \"Optimization for Source Molecule\": \"1. Replace the amide linkage (NC(=O)N) with a more flexible and potent linker like a urea (NC(=O)NC) or a sulfonamide (NS(=O)(=O)N) to enhance binding. 2. Modify the difluoroethylamine side chain (CNCC(F)F) to a bulkier hydrophobic group (e.g., cyclopropyl or tert-butyl) to better fit the hydrophobic pocket. 3. Replace the phenyl ring (c1ccccc1) with a smaller heterocycle (e.g., pyridine or thiazole) to improve solubility and binding efficiency.\",\n    \"Final Target Molecule\": \"CC(NC(=O)NC1CC1)c1cc2[nH]nc(CNS(=O)(=O)Nc3cccn3)c2cn1\"\n}\n```"
    },
    {
        "src_smiles": "CCCNC(=O)N1C(C#N)C(c2ccc(C3=CCCCC3)cc2)C1CO",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrrolidine ring (N1C(C#N)C(c2ccc(C3=CCCCC3)cc2)C1CO) with a cyano group (C#N), a benzyl group (c2ccc(C3=CCCCC3)cc2), and a hydroxymethyl group (CO) attached. The molecule also has a butyl chain (CCCN) connected to a carbonyl group (C=O) which is part of an amide linkage to the pyrrolidine nitrogen.\",\n    \"Property Analysis\": \"The molecule has potential for GSK3-beta inhibition due to the presence of a pyrrolidine ring and a benzyl group, which are common in kinase inhibitors. The cyano group may act as a hydrogen bond acceptor, enhancing binding affinity. However, the butyl chain and the amide linkage may not be optimal for binding to the GSK3-beta active site.\",\n    \"Limitation in Source Molecule for Property\": \"The butyl chain is flexible and may not contribute significantly to binding affinity or selectivity. The amide linkage might be metabolically unstable or not optimal for interaction with the kinase. The hydroxymethyl group could be modified to improve solubility or binding interactions.\",\n    \"Optimization for Source Molecule\": \"1. Replace the butyl chain with a more rigid or aromatic group to enhance binding affinity and selectivity. 2. Modify the amide linkage to a more stable or potent bioisostere, such as a sulfonamide or urea. 3. Consider replacing the hydroxymethyl group with a more polar or hydrogen-bonding group to improve interactions with the kinase. 4. Introduce additional substituents on the benzyl group to enhance hydrophobic interactions or hydrogen bonding with the target.\",\n    \"Final Target Molecule\": \"CN1C(C#N)C(c2ccc(C3=CCCCC3)cc2)C1CO\"\n}\n```"
    },
    {
        "src_smiles": "Cc1cc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)cc(C)n1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring connected to a fluorophenyl group and a piperazine-like moiety. The presence of fluorine and nitrogen atoms suggests potential for hydrogen bonding and hydrophobic interactions, which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule shows moderate GSK3-beta inhibition potential due to its ability to form hydrogen bonds and hydrophobic interactions. However, the inhibition may be limited by the flexibility of the piperazine-like moiety and the steric hindrance from the methyl groups on the phenyl ring.\",\n    \"Limitation in Source Molecule for Property\": \"The flexibility of the piperazine-like moiety may reduce binding affinity by allowing too much conformational freedom. Additionally, the methyl groups on the phenyl ring may cause steric clashes with the enzyme's active site, reducing inhibitory potency.\",\n    \"Optimization for Source Molecule\": \"To improve GSK3-beta inhibition, the piperazine-like moiety could be constrained into a more rigid structure to reduce conformational flexibility. The methyl groups on the phenyl ring could be replaced with smaller substituents or removed to reduce steric hindrance. Introducing additional hydrogen bond acceptors or donors could enhance binding affinity.\",\n    \"Final Target Molecule\": \"Cc1cc(-c2c(-c3ccc(F)cc3)ncn2CCN2CCOCC2)ccn1\"\n}\n```"
    },
    {
        "src_smiles": "COc1c(N2CCCC(N)C2)c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a benzimidazole core with a fluorine substituent, a morpholine ring (N2CCCC(N)C2), a carboxylic acid group (C(=O)O), and a cyclopropylmethyl group (C3CC3). The presence of the morpholine ring and the carboxylic acid suggests potential for hydrogen bonding interactions, which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the carboxylic acid and morpholine ring, which could aid in binding to the ATP-binding site of GSK3-beta. However, the fluorine substituent and cyclopropylmethyl group may not optimally contribute to binding affinity or selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"The morpholine ring may not provide optimal interactions with the hinge region of GSK3-beta. The cyclopropylmethyl group might not be the best fit for the hydrophobic pocket, and the fluorine substituent may not significantly enhance binding affinity. The carboxylic acid could lead to poor bioavailability due to high polarity.\",\n    \"Optimization for Source Molecule\": \"1. Replace the morpholine ring with a more rigid and planar heterocycle like pyridine or pyrimidine to better interact with the hinge region. 2. Replace the cyclopropylmethyl group with a larger hydrophobic group like a phenyl or naphthyl to better fill the hydrophobic pocket. 3. Consider replacing the fluorine with a more potent electron-withdrawing group like a nitro or cyano group to enhance binding affinity. 4. Replace the carboxylic acid with a bioisostere like a tetrazole or sulfonamide to maintain binding interactions while improving bioavailability.\",\n    \"Final Target Molecule\": \"COc1c(N2CCCC(N)C2)c(CN)c2c(=O)c(C(=O)O)cn(C3CC3)c12\"\n}\n```"
    },
    {
        "src_smiles": "CC1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C(C)CN1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central piperazine ring (CC1CN...CN1) with two fluorine-substituted aromatic rings (c2c(F)...c2F) and a carboxylic acid group (C(=O)O). The presence of a cyclopropyl group (C4CC4) attached to a nitrogen in the aromatic system is notable. The molecule has multiple hydrogen bond acceptors (N, O, F) and a hydrogen bond donor (COOH).\",\n    \"Property Analysis\": \"GSK3-beta inhibitors often require specific interactions with the ATP-binding pocket, including hydrogen bonding with key residues (e.g., Asp133, Val135) and hydrophobic interactions in the pocket. The current molecule shows potential with its hydrogen bond acceptors/donors and aromatic systems, but may lack optimal shape complementarity or additional interactions.\",\n    \"Limitation in Source Molecule for Property\": \"1) The carboxylic acid may be too polar/charged for optimal binding (pKa issue). 2) The cyclopropyl group's small size may not fully exploit hydrophobic pockets. 3) The fluorine substitutions are good for metabolic stability but don't contribute significantly to binding. 4) The piperazine ring's conformation may not be ideal for target engagement.\",\n    \"Optimization for Source Molecule\": \"1) Replace COOH with bioisostere like tetrazole or acyl sulfonamide to maintain H-bonding but improve permeability. 2) Expand cyclopropyl to bulkier hydrophobic group (e.g., phenyl, tert-butyl) to fill hydrophobic pocket. 3) Introduce additional H-bond donor/acceptor on aromatic ring to interact with backbone NH of Val135. 4) Constrain piperazine ring conformation via methylation or fusion to improve binding pose.\",\n    \"Final Target Molecule\": \"CC1CN(c2c(F)c(Nc3ccccc3)c4c(=O)c(C(=O)N5C(=NN=N5)C)cn(C6CC(C)(C)C6)c4c2F)C(C)CN1\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCc3cncs3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring fused with an imidazole ring (1H-imidazo[4,5-c]pyridine), substituted with a phenyl group, a urea linker, and a thiazole ring via an ether linkage. The molecule has hydrogen bond donors (NH groups) and acceptors (carbonyl and nitrogen atoms), which are crucial for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to its ability to form hydrogen bonds with the kinase's ATP-binding site. The urea linker and the nitrogen-rich heterocycles can interact with key residues like Asp133 and Val135. However, the thiazole ring's orientation and the flexibility of the ether linkage may limit optimal binding.\",\n    \"Limitation in Source Molecule for Property\": \"1. The ether linkage (O-CH2-thiazole) may introduce excessive flexibility, reducing binding affinity. 2. The thiazole ring's position might not optimally occupy the hydrophobic pocket. 3. The urea linker, while beneficial, could be replaced with a more rigid bioisostere to enhance potency.\",\n    \"Optimization for Source Molecule\": \"1. Replace the ether linkage with a more rigid linker (e.g., direct C-C bond or amide) to reduce flexibility. 2. Substitute the thiazole with a bulkier hydrophobic group (e.g., substituted phenyl or naphthyl) to better fill the hydrophobic pocket. 3. Replace the urea linker with a sulfonamide or amide to maintain hydrogen bonding while improving metabolic stability. 4. Introduce a methyl or fluorine on the phenyl ring to enhance lipophilic interactions.\",\n    \"Final Target Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(Cc3cncs3)c2cn1)c1ccc(F)cc1\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(S(C)(=O)=O)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring with a sulfonyl group (S(=O)(=O)-) attached, an aromatic phenyl ring, and a urea linkage (NC(=O)N). The sulfonyl group is electron-withdrawing, and the phenyl ring provides hydrophobicity. The molecule has hydrogen bond donors (NH) and acceptors (C=O, SO2).\",\n    \"Property Analysis\": \"GSK3-beta inhibition often requires molecules with specific hydrogen bonding interactions (e.g., with Lys85, Asp133) and hydrophobic interactions (e.g., with Val70, Leu188). The sulfonyl group may not optimally fit the ATP-binding pocket, and the urea linkage might limit conformational flexibility.\",\n    \"Limitation in Source Molecule for Property\": \"1. The sulfonyl group is too polar and may reduce cell permeability. 2. The urea linkage is rigid and may restrict binding to the kinase's hinge region. 3. The phenyl ring lacks substituents for optimal hydrophobic interactions.\",\n    \"Optimization for Source Molecule\": \"1. Replace the sulfonyl group with a less polar but still H-bond accepting group (e.g., carbonyl or heterocycle). 2. Modify the urea linkage to a more flexible amide or introduce a methylene spacer. 3. Add small hydrophobic substituents (e.g., methyl, fluoro) to the phenyl ring for better van der Waals contacts.\",\n    \"Final Target Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(C=O)c2cn1)c1ccc(F)cc1\"\n}\n```"
    },
    {
        "src_smiles": "CC(C)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule features a central pyrimidine ring fused with a benzene ring, substituted with chlorine atoms and a tert-butylamino group. The structure includes a carbonyl group adjacent to the pyrimidine nitrogen, which may influence binding to GSK3-beta.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to its heterocyclic core and hydrogen bond acceptor/donor capabilities. However, the presence of bulky chlorine substituents and the tert-butyl group may limit optimal binding interactions with the kinase's active site.\",\n    \"Limitation in Source Molecule for Property\": \"The bulky chlorine atoms and tert-butyl group may cause steric hindrance, reducing binding affinity. The carbonyl group's position might not optimally interact with key residues in the GSK3-beta active site.\",\n    \"Optimization for Source Molecule\": \"1. Replace chlorine atoms with smaller, electron-withdrawing groups (e.g., fluorine) to reduce steric hindrance while maintaining electronic effects. 2. Modify the tert-butylamino group to a smaller, more flexible amine (e.g., isopropyl or cyclopropyl) to enhance binding pocket compatibility. 3. Introduce a hydrogen bond donor/acceptor near the carbonyl to strengthen interactions with the kinase's hinge region.\",\n    \"Final Target Molecule\": \"CC(C)Nc1ncc2cc(-c3c(F)cccc3F)c(=O)n(C)c2n1\"\n}\n```"
    },
    {
        "src_smiles": "Cn1c(-c2ccnc(Oc3ccccc3)n2)c(-c2ccc(F)cc2)c(=O)n1C",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a quinazolinone core (n1c(-c2ccnc(Oc3ccccc3)n2)c(-c2ccc(F)cc2)c(=O)n1C) with a fluorine-substituted phenyl ring and a methoxy-substituted pyridine ring. The quinazolinone scaffold is known to interact with the ATP-binding site of GSK3-beta.\",\n    \"Property Analysis\": \"The molecule shows moderate GSK3-beta inhibition due to the quinazolinone core, but the inhibition can be improved by optimizing the substituents for better binding affinity and selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy group on the pyridine ring may not provide optimal hydrogen bonding interactions with the kinase. The fluorine on the phenyl ring is a small substituent and may not contribute significantly to binding affinity.\",\n    \"Optimization for Source Molecule\": \"1. Replace the methoxy group on the pyridine ring with a more polar group like an amino or hydroxyl group to enhance hydrogen bonding with the kinase. 2. Replace the fluorine on the phenyl ring with a bulkier, more electron-withdrawing group like a trifluoromethyl or nitro group to improve binding affinity. 3. Consider adding a small alkyl or cycloalkyl group to the quinazolinone nitrogen to modulate solubility and selectivity.\",\n    \"Final Target Molecule\": \"Cn1c(-c2ccnc(N)c2)c(-c2ccc(CF3)cc2)c(=O)n1C\"\n}\n```"
    },
    {
        "src_smiles": "COc1cc(OC)cc(-c2nnc(SCC(=O)c3ccccc3)o2)c1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central 1,2,4-oxadiazole ring connected to a methoxy-substituted phenyl ring and a thioether-linked acetylphenyl group. The presence of electron-donating methoxy groups on the phenyl ring may influence electron density distribution.\",\n    \"Property Analysis\": \"GSK3-beta inhibitors often benefit from hydrogen bond donors/acceptors and planar aromatic systems for binding to the ATP pocket. The current molecule has hydrogen bond acceptors (oxadiazole N/O, carbonyl) but lacks strong donors.\",\n    \"Limitation in Source Molecule for Property\": \"1) No strong hydrogen bond donor groups for optimal kinase interaction 2) Flexible thioether linker may reduce binding affinity 3) Methoxy groups may be suboptimal for hydrophobic pocket interactions\",\n    \"Optimization for Source Molecule\": \"1) Replace thioether with more rigid amide linker 2) Introduce hydrogen bond donor (e.g., NH2) on oxadiazole 3) Replace methoxy with halogens for better hydrophobic interactions 4) Consider bioisosteric replacement of oxadiazole with imidazole\",\n    \"Final Target Molecule\": \"COc1cc(Cl)cc(-c2nnc(N)C(=O)c3ccccc3)c1\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCC3CCCO3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring fused with an imidazole ring (forming a purine-like scaffold), substituted with a phenyl group, a carbamoyl group, and an oxetane ring. The presence of hydrogen bond donors (NH) and acceptors (C=O, N) suggests potential for GSK3-beta interaction.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the oxetane and carbamoyl groups, but the phenyl ring may limit solubility. The imidazole NH and carbamoyl group could form hydrogen bonds with GSK3-beta's ATP-binding site, but steric hindrance from the oxetane may reduce binding affinity.\",\n    \"Limitation in Source Molecule for Property\": \"1) The oxetane ring may cause steric clashes in the binding pocket. 2) The phenyl group lacks electron-withdrawing substituents, potentially reducing \u03c0-stacking interactions. 3) The carbamoyl group's conformation may not optimally align with key residues.\",\n    \"Optimization for Source Molecule\": \"1) Replace oxetane with a smaller, more flexible ether (e.g., methoxy) to reduce steric hindrance. 2) Introduce electron-withdrawing groups (e.g., F, CF3) on the phenyl ring to enhance \u03c0-stacking. 3) Replace carbamoyl with a more rigid urea derivative to improve hydrogen bonding geometry.\",\n    \"Final Target Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(OCC)c2cn1)c1ccc(F)cc1\"\n}\n```"
    },
    {
        "src_smiles": "COCc1nc(NC(=O)NC(C)c2ccccc2)cc2[nH]nc(OC)c12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a benzimidazole core with an amide linkage to a phenyl ring and methoxy substituents. The benzimidazole core is a common pharmacophore in kinase inhibitors, and the amide linkage provides hydrogen bonding potential. The methoxy groups may influence solubility and binding affinity.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the benzimidazole core, which can interact with the ATP-binding site. However, the methoxy groups may limit optimal binding due to steric hindrance or lack of additional hydrogen bond donors/acceptors.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy groups may not provide optimal interactions with the kinase active site. The amide linkage, while beneficial, could be optimized for better hydrogen bonding or conformational flexibility. The phenyl ring lacks substituents that could enhance binding affinity or selectivity.\",\n    \"Optimization for Source Molecule\": \"1. Replace the methoxy groups with more polar or hydrogen-bonding groups (e.g., hydroxyl or amino) to enhance interactions with the kinase. 2. Modify the amide linkage to a sulfonamide or urea to improve hydrogen bonding. 3. Introduce electron-withdrawing or donating groups on the phenyl ring to modulate binding affinity and selectivity.\",\n    \"Final Target Molecule\": \"COc1nc(NC(=O)NC(C)c2ccc(Cl)cc2)cc2[nH]nc(O)c12\"\n}\n```"
    },
    {
        "src_smiles": "CC(=O)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a quinazolinone core with a dichlorophenyl substituent and an acetamido group. The quinazolinone scaffold is known to interact with the ATP-binding site of GSK3-beta, while the dichlorophenyl group may contribute to hydrophobic interactions.\",\n    \"Property Analysis\": \"The molecule shows moderate GSK3-beta inhibition due to its quinazolinone core, but the dichlorophenyl group may lead to off-target effects or poor solubility. The acetamido group could be optimized for better hydrogen bonding with the kinase.\",\n    \"Limitation in Source Molecule for Property\": \"The dichlorophenyl group may cause toxicity or poor pharmacokinetics. The acetamido group's orientation may not optimally interact with the hinge region of GSK3-beta. The molecule's solubility could be limited due to the hydrophobic dichlorophenyl group.\",\n    \"Optimization for Source Molecule\": \"1. Replace the dichlorophenyl group with a more polar substituent (e.g., pyridyl or morpholino) to improve solubility and reduce toxicity. 2. Modify the acetamido group to a more rigid amide or urea to enhance hinge region binding. 3. Introduce a small polar group (e.g., hydroxyl or methoxy) on the quinazolinone core to improve water solubility.\",\n    \"Final Target Molecule\": \"CC(=O)Nc1ncc2cc(-c3cnccc3)c(=O)n(C)c2n1\"\n}\n```"
    },
    {
        "src_smiles": "O=C(Nc1ccc(Cl)cc1)Nc1ccc(C(F)(F)F)cc1Cl",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule is a diaryl urea derivative with two aromatic rings connected via urea linkage. One ring is substituted with a chlorine atom and the other with a trifluoromethyl group and a chlorine atom. The urea group (N-C=O-N) is a known pharmacophore for kinase inhibition, including GSK3-beta.\",\n    \"Property Analysis\": \"The molecule has moderate size and lipophilicity, which may affect its binding affinity and selectivity for GSK3-beta. The presence of electron-withdrawing groups (Cl, CF3) can influence the electronic properties of the aromatic rings, potentially affecting interactions with the kinase active site.\",\n    \"Limitation in Source Molecule for Property\": \"The molecule may have suboptimal binding affinity due to the lack of additional hydrogen bond donors/acceptors or steric complementarity with the GSK3-beta active site. The trifluoromethyl group, while increasing lipophilicity, may not contribute significantly to binding interactions.\",\n    \"Optimization for Source Molecule\": \"Introduce a hydrogen bond donor/acceptor (e.g., hydroxyl or amino group) on one of the aromatic rings to enhance interactions with the kinase hinge region. Replace the trifluoromethyl group with a smaller, more polar group (e.g., methoxy or methyl) to improve selectivity and reduce lipophilicity. Consider adding a small alkyl or heterocyclic substituent to improve steric complementarity with the hydrophobic pocket of GSK3-beta.\",\n    \"Final Target Molecule\": \"O=C(Nc1ccc(Cl)cc1)Nc1ccc(OC)cc1Cl\"\n}\n```"
    },
    {
        "src_smiles": "CCN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)CC1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a piperazine ring (CCN1CCN), a fluorinated benzimidazole core (c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC), and a cyclopropyl group (C4CC4). The benzimidazole core is substituted with a carboxylic acid (C(=O)O) and a methoxy group (OC). The presence of the carboxylic acid suggests potential for hydrogen bonding, while the fluorine atom may contribute to binding affinity through hydrophobic interactions.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the presence of a benzimidazole core, which is a known pharmacophore for kinase inhibition. The carboxylic acid can form hydrogen bonds with the kinase's active site, and the fluorine atom may enhance binding through hydrophobic interactions. However, the methoxy group and cyclopropyl substituent might not optimally contribute to binding affinity or selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy group (OC) may not provide optimal steric or electronic interactions with the GSK3-beta active site. The cyclopropyl group (C4CC4) might not be the most effective substituent for enhancing binding affinity or selectivity. Additionally, the piperazine ring (CCN1CCN) could introduce conformational flexibility that may not be ideal for tight binding.\",\n    \"Optimization for Source Molecule\": \"1. Replace the methoxy group (OC) with a more polar or hydrogen-bonding group like a hydroxyl (OH) or an amine (NH2) to enhance interactions with the active site. 2. Replace the cyclopropyl group (C4CC4) with a bulkier or more polar group like a phenyl or a pyridine ring to improve binding affinity and selectivity. 3. Modify the piperazine ring (CCN1CCN) to reduce conformational flexibility, such as by introducing a rigidifying element or replacing it with a more constrained ring system.\",\n    \"Final Target Molecule\": \"CCN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CCN)cc3c2O)CC1\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring with an amino group and a trifluoroethylamine substituent. It also has a phenyl ring attached via an amino linker. The presence of the trifluoroethylamine group suggests potential interactions with the GSK3-beta binding site, while the phenyl ring may contribute to hydrophobic interactions.\",\n    \"Property Analysis\": \"The molecule shows moderate GSK3-beta inhibition due to the presence of the trifluoroethylamine group, which can form hydrogen bonds and hydrophobic interactions with the kinase. However, the inhibition may be limited by the flexibility of the linker and the lack of additional polar groups to enhance binding affinity.\",\n    \"Limitation in Source Molecule for Property\": \"The main limitations are the flexibility of the linker between the pyrimidine and phenyl rings, which may reduce binding affinity, and the lack of additional polar or charged groups to strengthen interactions with the GSK3-beta active site.\",\n    \"Optimization for Source Molecule\": \"To improve GSK3-beta inhibition, we can: 1) Replace the flexible linker with a more rigid structure to reduce entropy loss upon binding. 2) Introduce additional polar or charged groups to enhance hydrogen bonding with the kinase. 3) Optimize the trifluoroethylamine group for better hydrophobic interactions.\",\n    \"Final Target Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(CNC(C(F)(F)F)c2cn1)c1ccccc1\"\n}\n```"
    },
    {
        "src_smiles": "COC(C)(C)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrazolo[1,5-a]pyrimidine core with a substituted phenyl ring and a methoxy group. The structure includes hydrogen bond donors (NH) and acceptors (C=O, N) which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule has moderate hydrogen bonding capacity and lipophilicity, which are crucial for binding to the ATP-binding site of GSK3-beta. However, the methoxy group may not optimally contribute to binding affinity or selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy group (COC(C)(C)) is bulky and may not optimally fit into the hydrophobic pocket of GSK3-beta. Additionally, the phenyl ring substitution may not provide sufficient interactions with key residues in the binding site.\",\n    \"Optimization for Source Molecule\": \"Replace the methoxy group with a smaller, more polar group like a hydroxyl or amine to enhance hydrogen bonding with the kinase. Introduce a halogen or small hydrophobic group on the phenyl ring to improve hydrophobic interactions with the binding pocket.\",\n    \"Final Target Molecule\": \"COC1=NC2=C(NC(=O)NC(C)C3=CC=CC=C3Cl)C=CN=N2C1O\"\n}\n```"
    },
    {
        "src_smiles": "O=C(Nc1ncc(CCNc2ncnc3ccsc23)s1)NC1CCCCC1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central thiazole ring (s1) connected to a piperidine ring (C1CCCCC1) via a urea linkage (N-C=O-N). The thiazole ring is further substituted with an ethylenediamine linker (CCN) connected to a purine-like bicyclic system (ncnc3ccsc23).\",\n    \"Property Analysis\": \"The molecule has potential for GSK3-beta inhibition due to the presence of hydrogen bond donors/acceptors (urea, thiazole N, purine-like system) and aromatic rings for hydrophobic interactions. However, the flexibility of the ethylenediamine linker and piperidine ring may reduce binding affinity.\",\n    \"Limitation in Source Molecule for Property\": \"1) The ethylenediamine linker may introduce excessive flexibility, reducing optimal binding. 2) The piperidine ring's conformational freedom may decrease target specificity. 3) The thiazole sulfur could potentially cause metabolic instability.\",\n    \"Optimization for Source Molecule\": \"1) Replace the ethylenediamine linker with a more rigid aromatic or heteroaromatic spacer to reduce flexibility. 2) Constrain the piperidine ring into a more rigid bicyclic system. 3) Replace the thiazole with a more stable oxazole ring to improve metabolic stability while maintaining H-bonding capability.\",\n    \"Final Target Molecule\": \"O=C(Nc1ncc(CNc2ncnc3ccnc23)s1)NC1CCC2CCCC12\"\n}\n```"
    },
    {
        "src_smiles": "O=C(Nc1cc(-c2ccccc2)ccc1O)c1ccc(CN2CCOCC2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a central amide linkage connecting two aromatic rings. One ring is a phenol derivative with a phenyl substituent, and the other is a benzene ring with a morpholine substituent via a methylene linker. The molecule has hydrogen bond donors (amide NH and phenol OH) and acceptors (carbonyl and ether oxygens), which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the presence of the amide and phenol groups, which could aid in binding to the ATP-binding site of GSK3-beta. The morpholine group may contribute to solubility but could also introduce flexibility that might reduce binding affinity.\",\n    \"Limitation in Source Molecule for Property\": \"The morpholine group, while improving solubility, may not optimally fit the hydrophobic pocket of GSK3-beta. The phenol group's acidity might lead to metabolic instability. The flexibility of the methylene linker could reduce binding affinity by increasing entropy upon binding.\",\n    \"Optimization for Source Molecule\": \"1. Replace the morpholine with a more rigid and hydrophobic group like a piperidine or a substituted phenyl to better fit the hydrophobic pocket. 2. Replace the phenol with a bioisostere like a benzimidazole to improve metabolic stability while maintaining hydrogen bonding. 3. Introduce a halogen or a small alkyl group on the phenyl ring to enhance hydrophobic interactions.\",\n    \"Final Target Molecule\": \"O=C(Nc1cc(-c2ccccc2)cc1N1CCCCC1)c1ccc(CN2CCCCC2)cc1\"\n}\n```"
    },
    {
        "src_smiles": "COc1ccc(C(O)(Cn2ccnc2)c2ccc(Br)cc2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central tertiary alcohol connected to a brominated phenyl ring and a methoxy-substituted phenyl ring, with a piperazine-like moiety (Cn2ccnc2) attached to the alcohol. The presence of a bromine atom suggests potential for halogen bonding, while the methoxy group may contribute to solubility and hydrogen bonding.\",\n    \"Property Analysis\": \"GSK3-beta inhibitors often feature hydrogen bond donors/acceptors and aromatic systems for binding to the ATP pocket. The current molecule has hydrogen bond acceptors (oxygen in methoxy and piperazine-like nitrogen) but lacks strong hydrogen bond donors, which are crucial for GSK3-beta inhibition.\",\n    \"Limitation in Source Molecule for Property\": \"1. Tertiary alcohol may limit hydrogen bonding potential. 2. Bromine, while potentially beneficial for binding, may not optimally interact with GSK3-beta. 3. The piperazine-like moiety is not a typical pharmacophore for GSK3-beta inhibition.\",\n    \"Optimization for Source Molecule\": \"1. Replace tertiary alcohol with a secondary alcohol or amine to introduce a hydrogen bond donor. 2. Replace bromine with a more polar group (e.g., nitrile or amide) to enhance binding. 3. Modify the piperazine-like moiety to a more rigid heterocycle (e.g., pyridine or imidazole) to improve binding affinity. 4. Consider adding a sulfonamide or urea group for additional hydrogen bonding.\",\n    \"Final Target Molecule\": \"COc1ccc(C(N)(Cn2ccnc2)c2ccc(C#N)cc2)cc1\"\n}\n```"
    },
    {
        "src_smiles": "CC1CN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)CCN1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a piperazine ring (CC1CN...CCN1) linked to a chlorinated, fluorinated, and carboxylated quinoline-like structure (c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl). The presence of a carboxyl group (C(=O)O) suggests potential for hydrogen bonding, while the fluorine and chlorine atoms may contribute to lipophilicity and binding affinity.\",\n    \"Property Analysis\": \"GSK3-beta inhibition often requires molecules that can fit into the ATP-binding pocket of the kinase, typically involving hydrogen bond donors/acceptors and hydrophobic interactions. The current molecule has a carboxyl group (hydrogen bond acceptor/donor) and halogen atoms (hydrophobic interactions), but the overall size and flexibility may limit optimal binding.\",\n    \"Limitation in Source Molecule for Property\": \"1. The carboxyl group may be too polar, reducing cell permeability. 2. The cyclobutyl group (C4CC4) on the quinoline nitrogen might sterically hinder binding. 3. The piperazine ring's flexibility could lead to entropic penalties upon binding. 4. The chlorine atom's position may not optimally contribute to binding affinity.\",\n    \"Optimization for Source Molecule\": \"1. Replace the carboxyl group with a bioisostere like tetrazole or sulfonamide to maintain hydrogen bonding while improving lipophilicity. 2. Replace the cyclobutyl group with a smaller methyl group to reduce steric hindrance. 3. Constrain the piperazine ring by fusing it into a more rigid structure (e.g., diazabicyclo[2.2.2]octane). 4. Reposition the chlorine atom to a meta position relative to the fluorine for better hydrophobic complementarity.\",\n    \"Final Target Molecule\": \"CC1CN2CCC(N1)c3cc(F)cc4c3Cl)n(C)c(=O)c4C(=O)N1CCN(C)CC1\"\n}\n```"
    },
    {
        "src_smiles": "CN1CCN(c2ncc3nc(CCc4ccccc4)c(=O)n(C)c3n2)CC1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central piperazine ring (CN1CCN...CC1) linked to a bicyclic heteroaromatic system (c2ncc3nc...n2) with a phenyl ring substituent (CCc4ccccc4). The bicyclic system includes a pyrimidine-like core with a carbonyl group (c(=O)n) and methyl substitution (n(C)).\",\n    \"Property Analysis\": \"The molecule has moderate size (MW ~350) and lipophilicity (cLogP ~3.5), with hydrogen bond acceptors (N, O) but no strong donors. The rigid bicyclic system may limit binding flexibility to GSK3-beta's ATP pocket.\",\n    \"Limitation in Source Molecule for Property\": \"1) The methyl group on the pyrimidine nitrogen may sterically hinder binding. 2) The phenyl ring lacks polar substituents for optimal interactions with the hinge region. 3) The piperazine linker may not optimally position the pharmacophores.\",\n    \"Optimization for Source Molecule\": \"1) Replace N-methyl with H to reduce sterics. 2) Introduce a hydrogen bond donor (e.g., NH2) at the phenyl para-position. 3) Replace piperazine with a more constrained spacer (e.g., piperidine). 4) Add a sulfonyl group to the bicyclic system for hinge interaction.\",\n    \"Final Target Molecule\": \"CN1CCC(Nc2ncc3nc(CCc4ccc(N)cc4)c(=O)nc3n2)CC1\"\n}\n```"
    },
    {
        "src_smiles": "CCC(C)(C)Nc1c(C#N)cnc2cnc(NCc3cccnc3)cc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring (c1c(C#N)cnc2cnc(NCc3cccnc3)cc12) with a cyano group (C#N) and an aminopropyl chain (CCC(C)(C)N) attached. The pyrimidine ring is further substituted with a piperazine-like moiety (NNc3cccnc3) via a methylene bridge (CH2).\",\n    \"Property Analysis\": \"The molecule has potential for GSK3-beta inhibition due to the presence of hydrogen bond acceptors (nitrogen atoms in the pyrimidine ring and cyano group) and donors (amine group). However, the bulky tert-butyl group (CCC(C)(C)) may hinder binding to the active site.\",\n    \"Limitation in Source Molecule for Property\": \"The tert-butyl group (CCC(C)(C)) is too bulky and may reduce binding affinity to GSK3-beta. The piperazine-like moiety (NNc3cccnc3) may also be suboptimal for target interaction.\",\n    \"Optimization for Source Molecule\": \"1. Replace the tert-butyl group with a smaller, more flexible alkyl group (e.g., isopropyl or ethyl) to improve binding. 2. Modify the piperazine-like moiety to a more rigid and planar heterocycle (e.g., pyridine or pyrimidine) to enhance \u03c0-stacking interactions. 3. Introduce additional hydrogen bond donors/acceptors (e.g., hydroxyl or carbonyl groups) to improve target interaction.\",\n    \"Final Target Molecule\": \"CC(C)Nc1c(C#N)cnc2cnc(NCc3ccncc3)cc12\"\n}\n```"
    },
    {
        "src_smiles": "CC(C(=O)Nc1ncc(SCc2ncc(C(C)(C)C)o2)s1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a thiazole ring (with sulfur and nitrogen) linked to a substituted benzene ring and a tert-butyl group via a thioether linkage. The presence of the amide group (C(=O)N) suggests potential hydrogen bonding interactions, which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule shows moderate potential for GSK3-beta inhibition due to its ability to form hydrogen bonds and hydrophobic interactions. However, the bulky tert-butyl group might limit optimal binding to the active site of GSK3-beta.\",\n    \"Limitation in Source Molecule for Property\": \"The tert-butyl group is too bulky, potentially causing steric hindrance and reducing binding affinity. The thioether linkage might also be metabolically unstable, affecting the molecule's pharmacokinetic properties.\",\n    \"Optimization for Source Molecule\": \"Replace the tert-butyl group with a smaller, more polar group (e.g., isopropyl or cyclopropyl) to reduce steric hindrance and improve binding. Consider replacing the thioether linkage with a more stable ether or amine linkage to enhance metabolic stability. Introduce additional hydrogen bond donors/acceptors (e.g., hydroxyl or amino groups) to strengthen interactions with GSK3-beta.\",\n    \"Final Target Molecule\": \"CC(C(=O)Nc1ncc(OCC2ncc(C(C)C)o2)s1)c1ccccc1\"\n}\n```"
    },
    {
        "src_smiles": "CC(C)n1cnc2c(NCc3ccccc3)nc(I)nc21",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule is a purine derivative with a phenyl group attached via an aminoethyl linker at the 6-position and an isopropyl group at the 1-position. The 2-position is substituted with an iodine atom.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the purine core, which is a known scaffold for kinase inhibitors. The phenyl group may contribute to binding affinity, but the isopropyl group and iodine might limit optimal interactions with the kinase.\",\n    \"Limitation in Source Molecule for Property\": \"The isopropyl group at the 1-position may be too bulky, potentially causing steric hindrance. The iodine at the 2-position, while providing electron-withdrawing effects, may not be optimal for hydrogen bonding or electrostatic interactions with the kinase active site.\",\n    \"Optimization for Source Molecule\": \"Replace the isopropyl group with a smaller methyl group to reduce steric hindrance. Substitute the iodine with a more polar group like an amino or hydroxyl group to enhance hydrogen bonding potential. The phenyl group can be retained or modified with electron-donating or withdrawing groups to fine-tune binding affinity.\",\n    \"Final Target Molecule\": \"CCn1cnc2c(NCc3ccccc3)nc(N)nc21\"\n}\n```"
    },
    {
        "src_smiles": "COCCSc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a benzimidazole core (Sc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12) with a methoxyethyl substituent (COCCS). The benzimidazole is substituted with a urea linkage (NC(=O)NC) connected to a phenyl ring (c3ccccc3).\",\n    \"Property Analysis\": \"The benzimidazole core is a known pharmacophore for kinase inhibition, including GSK3-beta. The urea linkage may contribute to hydrogen bonding interactions with the kinase. However, the methoxyethyl group may not optimally interact with the hydrophobic pocket of GSK3-beta.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxyethyl substituent (COCCS) may not provide sufficient hydrophobic interactions or optimal steric fit in the GSK3-beta binding site. Additionally, the urea linkage, while capable of hydrogen bonding, may not be the most potent moiety for GSK3-beta inhibition.\",\n    \"Optimization for Source Molecule\": \"1. Replace the methoxyethyl group with a more hydrophobic and bulky group (e.g., a phenyl or cyclohexyl) to enhance hydrophobic interactions with the GSK3-beta binding site. 2. Modify the urea linkage to a more potent hydrogen bond acceptor/donor pair, such as an amide or sulfonamide. 3. Introduce a halogen (e.g., fluorine or chlorine) on the phenyl ring to improve binding affinity through halogen bonding or enhanced hydrophobic interactions.\",\n    \"Final Target Molecule\": \"COc1ccc(CCSc2n[nH]c3cc(NC(=O)C(C)c4ccccc4Cl)ncc23)cc1\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCC3CCOCC3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring (c1cc2[nH]nc(OCC3CCOCC3)c2cn1) with an attached phenyl ring (c1ccccc1) and a urea linkage (NC(=O)N). The oxygen-containing tetrahydropyran ring (OCC3CCOCC3) is linked to the pyrimidine ring.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the presence of hydrogen bond donors (NH, OH) and acceptors (C=O, N, O), which can interact with the kinase's ATP-binding site. The aromatic rings may contribute to hydrophobic interactions.\",\n    \"Limitation in Source Molecule for Property\": \"The urea linkage (NC(=O)N) may reduce metabolic stability. The tetrahydropyran ring (OCC3CCOCC3) might limit solubility or binding affinity due to its bulkiness. The lack of a strong hydrogen bond acceptor/donor pair near the phenyl ring could reduce potency.\",\n    \"Optimization for Source Molecule\": \"1. Replace the urea linkage with a more stable amide or heterocyclic scaffold (e.g., pyrazole or triazole) to improve metabolic stability. 2. Modify the tetrahydropyran ring to a smaller, more polar group (e.g., morpholine) to enhance solubility and binding. 3. Introduce a hydrogen bond donor/acceptor (e.g., OH, NH2) on the phenyl ring to improve interactions with the kinase's hinge region. 4. Consider fluorination of the phenyl ring to enhance potency and metabolic stability.\",\n    \"Final Target Molecule\": \"CC(NC(=O)c1cnc2[nH]nc(OCC3CNCCO3)c2n1)c1ccc(F)cc1\"\n}\n```"
    },
    {
        "src_smiles": "CC(=O)c1ccc(-c2cccc(COC3COc4nc([N+](=O)[O-])cn4C3)c2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains an acetyl group (CC(=O)), a phenyl ring connected to another phenyl ring via a single bond, and a complex heterocyclic system with a nitro group ([N+](=O)[O-]) and an ether linkage (COC3COc4). The presence of the nitro group and the heterocyclic system suggests potential for hydrogen bonding and polar interactions, which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the nitro group and the heterocyclic system, which could facilitate binding to the active site of GSK3-beta. However, the acetyl group and the ether linkage might reduce the molecule's overall hydrophilicity, potentially affecting its solubility and bioavailability.\",\n    \"Limitation in Source Molecule for Property\": \"The acetyl group may not contribute significantly to GSK3-beta inhibition and could be metabolically unstable. The nitro group, while polar, might introduce toxicity concerns. The heterocyclic system, although complex, may not optimally fit the GSK3-beta active site due to steric hindrance or suboptimal hydrogen bonding patterns.\",\n    \"Optimization for Source Molecule\": \"1. Replace the acetyl group with a more polar and stable group like a carboxylic acid or an amide to enhance binding and solubility. 2. Consider replacing the nitro group with a sulfonamide or a cyano group to maintain polarity while reducing potential toxicity. 3. Simplify the heterocyclic system to reduce steric hindrance and improve fit within the GSK3-beta active site. 4. Introduce additional hydrogen bond donors or acceptors to enhance interactions with the kinase.\",\n    \"Final Target Molecule\": \"CC(=O)c1ccc(-c2cccc(C(=O)N3CCOCC3)c2)cc1\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring (c1cc2[nH]nc(CNCC(F)(F)F)c2cn1) with a urea linkage (NC(=O)N) to a phenyl ring (c1ccccc1) and a trifluoroethylamine side chain (CNCC(F)(F)F). The pyrimidine ring is a common scaffold in kinase inhibitors, and the urea group can form hydrogen bonds with the kinase.\",\n    \"Property Analysis\": \"The molecule has potential for GSK3-beta inhibition due to the pyrimidine core and hydrogen-bonding groups. However, the trifluoroethylamine side chain may not optimally interact with the hydrophobic pocket of GSK3-beta, and the urea linkage might limit conformational flexibility.\",\n    \"Limitation in Source Molecule for Property\": \"1. The trifluoroethylamine side chain may not optimally fill the hydrophobic pocket of GSK3-beta. 2. The urea linkage may restrict conformational flexibility, reducing binding affinity. 3. The phenyl ring lacks substituents to enhance hydrophobic interactions with the kinase.\",\n    \"Optimization for Source Molecule\": \"1. Replace the trifluoroethylamine side chain with a bulkier hydrophobic group (e.g., cyclopentyl or phenyl) to better fit the hydrophobic pocket. 2. Replace the urea linkage with a more flexible amide or sulfonamide group to improve binding entropy. 3. Add electron-withdrawing substituents (e.g., F, Cl) to the phenyl ring to enhance hydrophobic interactions and potential hydrogen bonding.\",\n    \"Final Target Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(CNC3CCCC3)c2cn1)c1ccc(F)cc1\"\n}\n```"
    },
    {
        "src_smiles": "Cc1ccccc1-c1ccc(CC2NC(=O)c3cc(Cl)ccc3N(C)C2=O)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a biphenyl core with a substituted piperidine-2,6-dione (glutarimide) moiety attached via a methylene linker. The biphenyl system provides rigidity, while the glutarimide ring is a known pharmacophore for GSK3-beta inhibition. The molecule also has a chloro substituent on the phenyl ring of the glutarimide and dimethyl substitution on the nitrogen.\",\n    \"Property Analysis\": \"The molecule likely exhibits moderate GSK3-beta inhibition due to the presence of the glutarimide core, which can interact with the ATP-binding site. However, the chloro substituent and dimethyl group may not optimally contribute to binding affinity or selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"1) The chloro substituent may not provide optimal electronic or steric interactions with the target. 2) The dimethyl substitution on the glutarimide nitrogen could limit hydrogen bonding opportunities. 3) The biphenyl system may be too rigid, limiting conformational adaptability for optimal binding.\",\n    \"Optimization for Source Molecule\": \"1) Replace the chloro substituent with a more electron-withdrawing group (e.g., CF3) to enhance binding interactions. 2) Change the dimethyl group to a hydrogen or smaller alkyl group to allow for potential hydrogen bonding. 3) Introduce flexibility by replacing one phenyl ring with a heteroaromatic ring (e.g., pyridine) to improve solubility and binding adaptability. 4) Consider adding a hydrogen bond donor/acceptor to the biphenyl system to enhance interactions with the target.\",\n    \"Final Target Molecule\": \"Cc1ccc(Cc1ccc2NC(=O)c3cc(C(F)(F)F)ccc3NC2=O)cc1\"\n}\n```"
    },
    {
        "src_smiles": "COCC(O)CNC(=O)c1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a benzimidazole core (c1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12) with a carbamate linkage to a morpholine-like fragment (COCC(O)CNC(=O)). The benzimidazole is substituted with a phenyl group via a urea linkage (NC(=O)NC(C)c3ccccc3). The molecule has hydrogen bond donors (NH, OH) and acceptors (C=O, N, O), which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the presence of multiple hydrogen bond donors and acceptors. The benzimidazole core is a common pharmacophore in kinase inhibitors, suggesting potential for GSK3-beta inhibition. However, the morpholine-like fragment may not optimally interact with the kinase's ATP-binding site.\",\n    \"Limitation in Source Molecule for Property\": \"The morpholine-like fragment (COCC(O)CNC(=O)) may not provide optimal interactions with the hydrophobic region of the GSK3-beta ATP-binding site. The urea linkage (NC(=O)NC(C)) might introduce conformational flexibility, reducing binding affinity. The hydroxyl group (OH) could lead to metabolic instability.\",\n    \"Optimization for Source Molecule\": \"1. Replace the morpholine-like fragment with a more rigid and hydrophobic group (e.g., phenyl or heteroaryl) to better fit the ATP-binding site. 2. Replace the urea linkage with a more rigid amide or heterocycle to reduce flexibility. 3. Remove or mask the hydroxyl group to improve metabolic stability. 4. Introduce substituents on the benzimidazole core to enhance interactions with the kinase.\",\n    \"Final Target Molecule\": \"COc1ccc(CNC(=O)c2n[nH]c3cc(NC(=O)c4ccccc4)ncc23)cc1\"\n}\n```"
    },
    {
        "src_smiles": "CNc1ncnc(-c2cccnc2Oc2cc(C(=O)Nc3cccc(C(F)(F)F)c3)ccc2C)n1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule features a central pyrimidine ring (1,3,5-triazine) substituted with a methylamino group (CN) at position 1, a phenyl ring linked via an ether (O) and a carbonyl (C=O) group at position 5, and a trifluoromethyl-substituted phenyl ring attached via an amide (N-C=O) at position 3. The molecule has a moderate size (MW ~500) and contains both polar (amide, ether) and hydrophobic (aromatic rings, CF3) regions.\",\n    \"Property Analysis\": \"The molecule likely exhibits GSK3-beta inhibition due to the presence of the amide and pyrimidine moieties, which can form hydrogen bonds with the kinase. The trifluoromethyl group may enhance binding via hydrophobic interactions. However, the inhibition may be suboptimal due to steric hindrance from the bulky substituents and potential metabolic instability of the ether linkage.\",\n    \"Limitation in Source Molecule for Property\": \"1) The ether linkage (Oc2cc...) may be metabolically labile. 2) The trifluoromethyl group, while enhancing hydrophobicity, may be too bulky, limiting binding pocket accommodation. 3) The methylamino group (CN) on the pyrimidine may not optimally interact with the kinase's hinge region.\",\n    \"Optimization for Source Molecule\": \"1) Replace the ether linkage with a more stable bioisostere like a methylene (CH2) or amide (CONH) to improve metabolic stability. 2) Replace the trifluoromethyl with a smaller hydrophobic group (e.g., Cl or CH3) to reduce steric hindrance. 3) Modify the methylamino group to a hydrogen bond donor/acceptor like NH2 or OH to enhance hinge region binding. 4) Consider introducing a solubilizing group (e.g., morpholine) to improve pharmacokinetics.\",\n    \"Final Target Molecule\": \"CNc1ncnc(-c2cccnc2CC2cc(C(=O)Nc3cccc(C)c3)ccc2C)n1\"\n}\n```"
    },
    {
        "src_smiles": "CCOC(=O)C1(C(=O)NC(Cc2ccc(-c3ccccc3OC)cc2)C(=O)O)CCCO1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central gamma-lactam (5-membered ring with nitrogen and carbonyl) fused to a tetrahydrofuran (5-membered oxygen-containing ring). It has a phenyl ether substituent and an ester group, suggesting potential for hydrogen bonding and hydrophobic interactions.\",\n    \"Property Analysis\": \"GSK3-beta inhibitors typically require hydrogen bond donors/acceptors (e.g., NH, C=O) for ATP-competitive binding and aromatic/hydrophobic groups for affinity enhancement. The current structure has some features (lactam NH, multiple C=O) but may lack optimal spatial arrangement.\",\n    \"Limitation in Source Molecule for Property\": \"1) The ester group may reduce metabolic stability. 2) The phenyl ether linker could limit conformational rigidity. 3) The fused ring system may not optimally position pharmacophores for GSK3-beta binding.\",\n    \"Optimization for Source Molecule\": \"1) Replace ester with amide (better stability). 2) Replace phenyl ether with direct phenyl or constrained linker. 3) Introduce additional hydrogen bond donor (e.g., OH) on phenyl ring. 4) Consider adding small hydrophobic group (e.g., methyl) near lactam to enhance binding pocket interactions.\",\n    \"Final Target Molecule\": \"CNC(=O)C1(C(=O)NC(Cc2ccc(-c3ccc(O)cc3)cc2)C(=O)O)CCCO1\"\n}\n```"
    },
    {
        "src_smiles": "CC(C)CC(NC(c1ccc(-c2ccc(C#N)cc2)cc1)C(F)(F)F)C(=O)NCC#N",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a trifluoromethyl group (CF3), a cyano group (C#N), and an amide linkage. The presence of these groups suggests potential interactions with the GSK3-beta enzyme, particularly through hydrogen bonding and hydrophobic interactions.\",\n    \"Property Analysis\": \"The molecule shows moderate GSK3-beta inhibition due to the presence of the trifluoromethyl group and the cyano group, which can interact with the enzyme's active site. However, the inhibition may be limited by the flexibility of the molecule and the lack of optimal steric and electronic properties.\",\n    \"Limitation in Source Molecule for Property\": \"The main limitations are the flexibility of the alkyl chain and the lack of a rigid scaffold, which may reduce binding affinity. Additionally, the cyano group may not provide optimal hydrogen bonding interactions with the enzyme.\",\n    \"Optimization for Source Molecule\": \"To improve GSK3-beta inhibition, the molecule can be optimized by introducing a more rigid scaffold, such as a heterocyclic ring, to reduce flexibility and enhance binding. The cyano group can be replaced with a more potent hydrogen bond acceptor or donor, such as a carboxyl or sulfonamide group. The trifluoromethyl group can be retained or modified to enhance hydrophobic interactions.\",\n    \"Final Target Molecule\": \"CC(C)CC(NC(c1ccc(-c2ccc(C(=O)O)cc2)cc1)C(F)(F)F)C(=O)NCC(=O)O\"\n}\n```"
    },
    {
        "src_smiles": "Cc1c(F)ccc(C(=O)Nc2cc(C(=O)O)ccc2N2CCN(C)CC2)c1Cl",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central phenyl ring (c1) substituted with a methyl group (Cc1), fluorine (F), chlorine (Cl), and a carbonyl group linked to an aniline derivative (C(=O)Nc2). The aniline derivative itself is further substituted with a carboxylic acid (C(=O)O) and a dimethylaminoethyl group (N2CCN(C)CC2). This structure suggests potential for hydrogen bonding and ionic interactions due to the presence of the carboxylic acid and the tertiary amine.\",\n    \"Property Analysis\": \"The molecule's potential to inhibit GSK3-beta could be influenced by its ability to form hydrogen bonds and ionic interactions with the enzyme's active site. The presence of a carboxylic acid and a tertiary amine suggests that the molecule could interact with polar and charged residues in the binding pocket. However, the overall size and flexibility might affect its binding affinity and selectivity.\",\n    \"Limitation in Source Molecule for Property\": \"The carboxylic acid group (C(=O)O) might limit cell permeability due to its high polarity. Additionally, the dimethylaminoethyl group (N2CCN(C)CC2) could introduce undesired off-target interactions or reduce selectivity. The presence of both electron-withdrawing (F, Cl) and electron-donating (methyl, dimethylaminoethyl) groups might also affect the molecule's electronic distribution and binding affinity.\",\n    \"Optimization for Source Molecule\": \"To improve GSK3-beta inhibition, consider the following optimizations: 1) Replace the carboxylic acid with a bioisostere such as a tetrazole or sulfonamide to maintain hydrogen bonding potential while improving permeability. 2) Modify the dimethylaminoethyl group to a more rigid or less basic amine to reduce off-target effects. 3) Introduce additional hydrophobic groups to enhance binding affinity by interacting with hydrophobic pockets in the enzyme. 4) Explore the removal of the fluorine or chlorine to simplify the molecule and reduce potential metabolic liabilities.\",\n    \"Final Target Molecule\": \"Cc1c(Cl)ccc(C(=O)Nc2cc(C(=O)N3C=NN=N3)ccc2N2CCCC2)c1\"\n}\n```"
    },
    {
        "src_smiles": "CN1CCN(CCCNc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)CC1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a piperazine ring (CN1CCN...CC1) connected to a naphthyridine-like core (c2ncc3cc...n2) via a propylamine linker (CCCN). The naphthyridine core is substituted with a dichlorophenyl group (-c4c(Cl)cccc4Cl) and a methyl group on the nitrogen (N(C)). The molecule has multiple hydrogen bond acceptors (N, O) and donors (NH), and the dichlorophenyl group adds lipophilicity.\",\n    \"Property Analysis\": \"GSK3-beta inhibitors often require specific interactions with the ATP-binding site, including hydrogen bonding with key residues (e.g., Asp133, Val135) and hydrophobic interactions. The current molecule has potential for these interactions but may lack optimal geometry or affinity.\",\n    \"Limitation in Source Molecule for Property\": \"1. The propylamine linker may be too flexible, reducing binding efficiency. 2. The dichlorophenyl group might be overly lipophilic, affecting solubility. 3. The methyl group on the naphthyridine nitrogen could sterically hinder optimal binding. 4. The piperazine ring's basicity might lead to off-target interactions.\",\n    \"Optimization for Source Molecule\": \"1. Replace the propylamine linker with a more rigid structure (e.g., cyclopropyl or aryl spacer) to reduce flexibility. 2. Modify the dichlorophenyl group to a mono-chloro or fluorophenyl to balance lipophilicity. 3. Replace the N-methyl with a hydrogen or smaller group (e.g., H, F) to reduce steric hindrance. 4. Consider replacing the piperazine with a less basic heterocycle (e.g., morpholine) to improve selectivity.\",\n    \"Final Target Molecule\": \"CN1CCOCC1CCc2ncc3cc(-c4cc(Cl)ccc4)c(=O)n([H])c3n2\"\n}\n```"
    },
    {
        "src_smiles": "COc1cccc(Cl)c1-c1ccc(COC2COc3nc([N+](=O)[O-])cn3C2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a biphenyl core with a chlorophenyl and a methoxyphenyl group. The methoxyphenyl group is further substituted with a morpholine-like ring containing a nitro group. The presence of the nitro group and the morpholine-like ring suggests potential interactions with GSK3-beta, but the overall structure may lack optimal binding affinity and selectivity.\",\n    \"Property Analysis\": \"The nitro group and the morpholine-like ring may contribute to hydrogen bonding and electrostatic interactions with GSK3-beta. However, the chlorophenyl group may introduce steric hindrance or reduce solubility, potentially limiting the molecule's inhibitory activity.\",\n    \"Limitation in Source Molecule for Property\": \"The chlorophenyl group may reduce binding affinity due to steric hindrance or unfavorable hydrophobic interactions. The nitro group, while potentially beneficial for binding, may also contribute to metabolic instability or toxicity. The morpholine-like ring may not provide optimal interactions with the kinase active site.\",\n    \"Optimization for Source Molecule\": \"1. Replace the chlorophenyl group with a more polar or hydrogen-bonding group (e.g., hydroxyl or amide) to improve binding affinity and solubility. 2. Modify the nitro group to a more stable or bioisosteric group (e.g., cyano or trifluoromethyl) to maintain interactions while improving stability. 3. Optimize the morpholine-like ring by introducing additional hydrogen-bonding groups or rigidifying the structure to enhance binding specificity.\",\n    \"Final Target Molecule\": \"COc1cccc(O)c1-c1ccc(COC2COc3nc(C#N)cn3C2)cc1\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(C(=O)N3CC(=O)N(C)C3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring fused with an imidazole ring, which is substituted with a phenyl group and a urea linkage. The molecule also features a dimethylated hydantoin ring connected via an amide bond. Key functional groups include urea, amide, and aromatic rings, which are common in kinase inhibitors.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to its urea and amide groups, which can form hydrogen bonds with the kinase's active site. The aromatic rings may contribute to hydrophobic interactions. However, the dimethylated hydantoin ring might limit solubility and bioavailability.\",\n    \"Limitation in Source Molecule for Property\": \"The dimethylated hydantoin ring could reduce solubility and membrane permeability. The urea linkage, while beneficial for binding, might be metabolically unstable. The phenyl group's position may not optimally interact with hydrophobic pockets in GSK3-beta.\",\n    \"Optimization for Source Molecule\": \"1. Replace the dimethylated hydantoin ring with a more soluble and less sterically hindered group, such as a piperazine or morpholine ring. 2. Modify the urea linkage to a more stable amide or sulfonamide group. 3. Introduce a halogen or small alkyl group on the phenyl ring to enhance hydrophobic interactions with the kinase's hydrophobic pockets. 4. Consider adding a hydrogen bond donor or acceptor to improve binding affinity.\",\n    \"Final Target Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(C(=O)N3CCOCC3)c2cn1)c1ccc(Cl)cc1\"\n}\n```"
    },
    {
        "src_smiles": "COc1ccc(NC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central indole core substituted with a benzamide group and a methoxy phenyl ring. The presence of electron-donating methoxy groups and a chloro substituent on the benzamide ring may influence binding to GSK3-beta.\",\n    \"Property Analysis\": \"The molecule shows potential for GSK3-beta inhibition due to the presence of hydrogen bond acceptors (carbonyl groups) and aromatic rings that can engage in pi-pi stacking interactions. However, the methoxy groups may reduce binding affinity due to steric hindrance or unfavorable electronic effects.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy groups on the phenyl rings may limit binding affinity to GSK3-beta due to steric hindrance or suboptimal electronic effects. The chloro substituent on the benzamide ring may also not be optimal for binding.\",\n    \"Optimization for Source Molecule\": \"Replace the methoxy groups with smaller, more polar substituents like hydroxyl or amino groups to improve hydrogen bonding potential. Replace the chloro substituent with a more electron-withdrawing group like a nitro or cyano group to enhance binding interactions. Consider introducing a basic nitrogen in the indole core to improve solubility and binding affinity.\",\n    \"Final Target Molecule\": \"COc1ccc(NC(=O)Cc2c(C)n(C(=O)c3ccc(NO2)cc3)c3ccc(OH)cc23)cc1\"\n}\n```"
    },
    {
        "src_smiles": "COc1ccccc1N(C)c1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCN(C)CC2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a methoxy-substituted phenyl ring connected to a dimethylamino group, which is further linked to a pyridone ring. The pyridone ring is connected to a benzamide moiety with a piperazine substituent. The molecule has multiple hydrogen bond acceptors and donors, which could be important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule has moderate size and polarity, with several hydrogen bond donors and acceptors. The presence of the piperazine ring may contribute to solubility but could also introduce metabolic instability. The methoxy and dimethylamino groups may affect the molecule's electronic properties and binding affinity.\",\n    \"Limitation in Source Molecule for Property\": \"The methoxy group on the phenyl ring may not optimally contribute to GSK3-beta inhibition. The dimethylamino group could be metabolically unstable. The pyridone ring, while a good hydrogen bond acceptor, may not provide optimal steric or electronic interactions with the GSK3-beta active site.\",\n    \"Optimization for Source Molecule\": \"Replace the methoxy group with a more potent electron-withdrawing group like a fluorine or a cyano group to enhance binding affinity. Replace the dimethylamino group with a more stable and potent group like a morpholine or a piperidine to improve metabolic stability and binding. Modify the pyridone ring to a more rigid and potent heterocycle like a quinazoline or a pyrimidine to enhance interactions with the active site.\",\n    \"Final Target Molecule\": \"FC1=CC=C(C(=O)N2CCN(C3CCNCC3)CC2)C=C1N=C1C=NC(=O)C=C1\"\n}\n```"
    },
    {
        "src_smiles": "O=C(NC(Cc1ccc(O)cc1)C(=O)NCC1CC(Br)=NO1)OCc1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a benzyloxycarbonyl group (Cbz) attached to an amide, which is linked to a phenylalanine derivative with a brominated oxazoline ring. The presence of the bromine atom and the oxazoline ring suggests potential reactivity and steric hindrance issues.\",\n    \"Property Analysis\": \"The molecule's ability to inhibit GSK3-beta is likely hindered by the bulky brominated oxazoline ring, which may reduce binding affinity due to steric clashes with the enzyme's active site. The benzyloxycarbonyl group might also contribute to poor pharmacokinetic properties.\",\n    \"Limitation in Source Molecule for Property\": \"The brominated oxazoline ring introduces steric hindrance, potentially reducing binding affinity to GSK3-beta. The benzyloxycarbonyl group may lead to metabolic instability and poor bioavailability.\",\n    \"Optimization for Source Molecule\": \"Replace the brominated oxazoline ring with a smaller, less sterically demanding heterocycle like pyridine to improve binding affinity. Modify the benzyloxycarbonyl group to a more metabolically stable moiety, such as a tert-butyloxycarbonyl (Boc) group, to enhance pharmacokinetic properties.\",\n    \"Final Target Molecule\": \"O=C(NC(Cc1ccc(O)cc1)C(=O)NCC1=CC=CN1)OC(C)(C)C\"\n}\n```"
    },
    {
        "src_smiles": "Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-c2cnn(C)c2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a central biphenyl-like structure with a methyl group on one phenyl ring and a carboxamide group on the other. The biphenyl is connected to a thiazole ring bearing a propionic acid side chain and a pyrazole ring with a methyl substituent. The molecule has multiple aromatic rings, which may contribute to its planarity and potential for \u03c0-\u03c0 stacking interactions with GSK3-beta.\",\n    \"Property Analysis\": \"The presence of the carboxamide and carboxylic acid groups suggests potential hydrogen bonding interactions with the kinase. The aromatic systems may engage in hydrophobic interactions. However, the molecule's size and flexibility might limit its binding affinity and selectivity for GSK3-beta.\",\n    \"Limitation in Source Molecule for Property\": \"The propionic acid side chain may introduce excessive flexibility, reducing binding affinity. The methyl group on the pyrazole may not optimally contribute to binding. The carboxamide group's position may not be ideal for forming critical hydrogen bonds with the kinase's active site.\",\n    \"Optimization for Source Molecule\": \"1. Replace the propionic acid with a more rigid carboxylic acid-containing heterocycle (e.g., oxazole-4-carboxylic acid) to reduce flexibility and improve binding. 2. Substitute the pyrazole methyl group with a bulkier, more hydrophobic group (e.g., isopropyl) to enhance hydrophobic interactions. 3. Move the carboxamide group to a position that better aligns with key residues in the GSK3-beta active site. 4. Consider introducing a fluorine atom on the phenyl ring to improve binding affinity and metabolic stability.\",\n    \"Final Target Molecule\": \"Cc1cc(C(N)=O)ccc1-n1c(CC2=NC=C(O2)C(=O)O)cc1-c1ccc(-c2cnn(C(C)C)c2)cc1\"\n}\n```"
    },
    {
        "src_smiles": "CN1C(=O)C(Cc2ccc(-c3ccccc3[N+](=O)[O-])cc2)NC(=O)c2cc(Cl)ccc21",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central indole-2-one scaffold with a nitrobenzene substituent and a chlorophenyl group. The nitro group is electron-withdrawing, and the chlorophenyl group may contribute to steric hindrance.\",\n    \"Property Analysis\": \"GSK3-beta inhibitors often require specific interactions with the ATP-binding pocket, including hydrogen bonding and hydrophobic interactions. The nitro group may not be optimal for binding due to its strong electron-withdrawing nature and potential toxicity.\",\n    \"Limitation in Source Molecule for Property\": \"The nitro group could lead to off-target effects or metabolic instability. The chlorophenyl group might introduce excessive steric bulk, limiting optimal binding to GSK3-beta.\",\n    \"Optimization for Source Molecule\": \"Replace the nitro group with a hydrogen bond donor/acceptor like an amide or sulfonamide to improve binding affinity and reduce toxicity. Modify the chlorophenyl group to a smaller or more flexible substituent (e.g., methyl or methoxy) to reduce steric hindrance while maintaining hydrophobic interactions.\",\n    \"Final Target Molecule\": \"CN1C(=O)C(Cc2ccc(-c3ccccc3C(=O)NH2)cc2)NC(=O)c2cc(OC)ccc21\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(C(=O)NCC(O)C(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring (with NH and C=O groups) linked to a phenyl ring via an NC(=O)N bridge. It also has a fluorinated ethanol side chain attached to a secondary amide. The structure suggests potential hydrogen bond donors/acceptors (NH, C=O, OH) and hydrophobic regions (phenyl, fluorinated alkyl).\",\n    \"Property Analysis\": \"For GSK3-beta inhibition, key features include: 1) Aromatic/hydrophobic interactions with the ATP-binding pocket, 2) Hydrogen bonding with hinge region residues (typically via NH/C=O groups), 3) Optimal steric fit in the hydrophobic back pocket. The fluorinated side chain may contribute to binding but could be optimized for better pharmacokinetics.\",\n    \"Limitation in Source Molecule for Property\": \"1) The fluorinated ethanol side chain may have high desolvation penalty due to polarity. 2) The NC(=O)N linker might be too flexible, reducing binding affinity. 3) The phenyl ring lacks substituents for optimal hydrophobic interactions. 4) The pyrimidine NH may not optimally align with hinge region hydrogen bond acceptors.\",\n    \"Optimization for Source Molecule\": \"1) Replace fluorinated ethanol with a less polar hydrophobic group (e.g., cyclopropyl). 2) Rigidify the NC(=O)N linker by incorporating it into a bicyclic system. 3) Add electron-withdrawing substituents (e.g., Cl, CF3) to the phenyl ring for better \u03c0-stacking. 4) Modify pyrimidine to pyridine or add methyl groups to improve hinge binding.\",\n    \"Final Target Molecule\": \"CC1=NC(=NC2=C1N=C(NC(=O)N3CCCC3)C=N2)C4=CC=C(C=C4)Cl\"\n}\n```"
    },
    {
        "src_smiles": "CCCCCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a quinazolinone core with a dichlorophenyl substituent and a hexylamino side chain. The quinazolinone scaffold is known to interact with the ATP-binding site of GSK3-beta, while the dichlorophenyl group may contribute to hydrophobic interactions. The hexylamino side chain could be optimized for better binding affinity and selectivity.\",\n    \"Property Analysis\": \"The molecule shows moderate GSK3-beta inhibition due to the quinazolinone core, but the hexylamino side chain may not be optimal for binding affinity or pharmacokinetic properties. The dichlorophenyl group provides hydrophobic interactions but may be too bulky, limiting solubility.\",\n    \"Limitation in Source Molecule for Property\": \"1. The hexylamino side chain is too long and flexible, potentially reducing binding affinity and increasing off-target interactions. 2. The dichlorophenyl group may be too bulky, limiting solubility and membrane permeability. 3. Lack of hydrogen bond donors/acceptors in the side chain for additional interactions with GSK3-beta.\",\n    \"Optimization for Source Molecule\": \"1. Replace the hexylamino side chain with a shorter, more rigid aminoalkyl group (e.g., cyclopropylamino or aminomethyl) to improve binding affinity and reduce flexibility. 2. Replace one or both chlorine atoms with smaller halogens (e.g., fluorine) or polar groups to improve solubility. 3. Introduce a hydrogen bond donor/acceptor in the side chain to enhance interactions with the kinase hinge region.\",\n    \"Final Target Molecule\": \"CC1CNc2ncc3cc(-c4c(F)cccc4F)c(=O)n(C1)c3n2\"\n}\n```"
    },
    {
        "src_smiles": "CCOCn1oc(=O)c(-c2ccc(F)cc2)c1-c1ccnc(Oc2ccccc2O)n1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central oxazole ring (1,3-oxazole) with a carboxylate group and a fluorophenyl substituent. It also has a naphthyridine-like moiety (pyridine fused with a benzene ring) with an ether linkage to a phenol group. The molecule has multiple hydrogen bond acceptors (carbonyl, ether, oxazole nitrogen, pyridine nitrogen) and donors (phenolic OH).\",\n    \"Property Analysis\": \"GSK3-beta inhibitors typically require interactions with the ATP-binding pocket, which prefers planar, aromatic systems and hydrogen bond donors/acceptors. The current molecule has these features but may lack optimal steric and electronic complementarity.\",\n    \"Limitation in Source Molecule for Property\": \"1) The flexible ethoxy group (CCOC) may reduce binding affinity by increasing entropy loss upon binding. 2) The fluorophenyl group's position may not optimally interact with hydrophobic pockets. 3) The naphthyridine moiety's conformation may not perfectly align with the kinase's hinge region.\",\n    \"Optimization for Source Molecule\": \"1) Replace the ethoxy group with a rigid, planar heterocycle (e.g., pyrazole) to reduce flexibility. 2) Modify the fluorophenyl to a more extended aromatic system (e.g., naphthyl) for better hydrophobic interactions. 3) Introduce a methyl group ortho to the phenolic OH to enforce a bioactive conformation. 4) Consider replacing the oxazole with an imidazole to better mimic the adenine moiety of ATP.\",\n    \"Final Target Molecule\": \"Cc1nc2ccc(Oc3ccccc3O)nc2n1-c1ncc(-c2ccc3ccccc3c2)o1\"\n}\n```"
    },
    {
        "src_smiles": "COc1cc(Cc2cnc(N)nc2N)ccc1OCc1ccc(-c2csnn2)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule consists of a central phenyl ring connected to two substituents: one with a methoxy group and a pyrimidine-like ring (with amino and nitro groups), and the other with a methoxyethyl group and a thiazole ring. The molecule has potential hydrogen bond donors (NH) and acceptors (N, O, S), which are important for GSK3-beta inhibition.\",\n    \"Property Analysis\": \"The molecule shows moderate potential for GSK3-beta inhibition due to its hydrogen bonding capabilities and aromatic systems. However, the nitro group may introduce metabolic instability, and the thiazole ring's electronic properties might not be optimal for binding.\",\n    \"Limitation in Source Molecule for Property\": \"1. The nitro group can be metabolically unstable. 2. The thiazole ring may not provide optimal electronic or steric interactions with GSK3-beta. 3. The methoxy groups may limit solubility or binding affinity.\",\n    \"Optimization for Source Molecule\": \"1. Replace the nitro group with a more stable electron-withdrawing group like a cyano or amide. 2. Modify the thiazole ring to a more GSK3-beta favorable heterocycle like pyridine or pyrimidine. 3. Introduce a polar group (e.g., hydroxyl or amine) to improve solubility and binding interactions.\",\n    \"Final Target Molecule\": \"COc1cc(Cc2cnc(N)nc2C#N)ccc1OCc1ccc(-c2nccn2)cc1\"\n}\n```"
    },
    {
        "src_smiles": "COCCn1c(=O)c(-c2ccc(OC)cc2)nc2cnc(OCc3ccccc3)nc21",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a central pyrimidine ring (with carbonyl and nitrogen atoms) connected to a methoxy-substituted phenyl ring and a methoxybenzyl-substituted pyridine ring. The structure includes multiple aromatic systems and ether linkages, which may influence binding to GSK3-beta.\",\n    \"Property Analysis\": \"The molecule has moderate size (MW ~400) and lipophilicity (cLogP ~3.5), with hydrogen bond acceptors (carbonyl, ethers, nitrogens) but no strong hydrogen bond donors. The methoxy groups and aromatic systems may contribute to \u03c0-stacking interactions with the kinase.\",\n    \"Limitation in Source Molecule for Property\": \"1) Lack of strong hydrogen bond donors for key interactions with kinase hinge region. 2) The methoxy groups may be too small for optimal hydrophobic pocket filling. 3) The benzyloxy group could cause steric clashes or suboptimal orientation. 4) Moderate lipophilicity may limit solubility.\",\n    \"Optimization for Source Molecule\": \"1) Replace one methoxy with a hydrogen bond donor (e.g., hydroxyl or NH) for hinge binding. 2) Extend hydrophobic substituents (e.g., replace OMe with OPr or cyclopentyloxy) for better pocket filling. 3) Replace benzyloxy with a more constrained bicyclic system (e.g., indole) to maintain aromaticity while reducing flexibility. 4) Consider adding a basic nitrogen for salt formation and solubility.\",\n    \"Final Target Molecule\": \"COCCn1c(=O)c(-c2ccc(O)cc2)nc2cnc(OCc3c[nH]c4ccccc34)nc21\"\n}\n```"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCCOC(F)(F)F)c2cn1)c1ccc(F)cc1",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a pyrazolo[1,5-a]pyrimidine core with a trifluoroethoxy substituent, a urea linker, and a p-fluorophenyl group attached to an ethylamine. The pyrazolo[1,5-a]pyrimidine core is a known pharmacophore for kinase inhibition, including GSK3-beta.\",\n    \"Property Analysis\": \"The molecule has moderate polarity due to the urea and pyrazolo[1,5-a]pyrimidine core, which may aid in binding to the ATP pocket of GSK3-beta. The trifluoroethoxy group could enhance metabolic stability but may also increase lipophilicity.\",\n    \"Limitation in Source Molecule for Property\": \"The urea linker may introduce flexibility and reduce binding affinity. The p-fluorophenyl group is small and may not optimally interact with hydrophobic pockets in the GSK3-beta binding site. The trifluoroethoxy group's bulkiness could sterically hinder optimal binding.\",\n    \"Optimization for Source Molecule\": \"1. Replace the urea linker with a more rigid amide or heterocyclic linker to reduce flexibility. 2. Replace the p-fluorophenyl group with a bulkier hydrophobic group (e.g., naphthyl or biphenyl) to enhance hydrophobic interactions. 3. Modify the trifluoroethoxy group to a smaller or more polar group (e.g., methoxy or hydroxyethoxy) to reduce steric hindrance and improve solubility.\",\n    \"Final Target Molecule\": \"CC(NC(=O)c1cc2[nH]nc(OCC)c2cn1)c1ccc(C3=CC=CC=C3)cc1\"\n}\n```"
    },
    {
        "src_smiles": "Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(NCCCN3CCOCC3)nc21",
        "prop": "gsk",
        "json_results": "```json\n{\n    \"Structural Analysis of Source Molecule\": \"The source molecule contains a dichlorophenyl ring attached to a purine-like scaffold with a piperazine substituent. The presence of chlorine atoms suggests potential for hydrophobic interactions, while the purine-like core may mimic ATP binding. The piperazine tail could offer flexibility for binding interactions.\",\n    \"Property Analysis\": \"GSK3-beta inhibitors often require specific interactions with the ATP-binding site, including hydrogen bonding with key residues and hydrophobic interactions. The dichlorophenyl group may provide hydrophobic contacts, but the piperazine tail might not optimally position for necessary interactions.\",\n    \"Limitation in Source Molecule for Property\": \"The piperazine substituent (NCCCN3CCOCC3) may be too flexible or bulky, potentially reducing binding affinity or selectivity. The dichlorophenyl group, while hydrophobic, might not optimally fit the hydrophobic pocket of GSK3-beta.\",\n    \"Optimization for Source Molecule\": \"1. Replace the piperazine tail with a more rigid and compact amine (e.g., pyrrolidine) to reduce flexibility and improve binding. 2. Modify the dichlorophenyl group to a smaller hydrophobic group (e.g., methyl or trifluoromethyl) to better fit the hydrophobic pocket. 3. Introduce a hydrogen bond donor/acceptor (e.g., hydroxyl or carbonyl) on the purine-like core to enhance interactions with the kinase hinge region.\",\n    \"Final Target Molecule\": \"Cn1c(=O)c(-c2c(C(F)(F)F)cccc2)cc2cnc(NC3CCNC3)nc21\"\n}\n```"
    }
]